

Nucleotide Sequence of the Gene for Human Factor IX (Antihemophilic Factor B)[†]

Shinji Yoshitake,[‡] Barbara G. Schach, Donald C. Foster, Earl W. Davie, and Kotoku Kurachi*

Department of Biochemistry, University of Washington, Seattle, Washington 98195

Received March 12, 1985

ABSTRACT: Two different human genomic DNA libraries were screened for the gene for blood coagulation factor IX by employing a cDNA for the human protein as a hybridization probe. Five overlapping λ phages were identified that contained the gene for factor IX. The complete DNA sequence of about 38 kilobases for the gene and the adjacent 5' and 3' flanking regions was established by the dideoxy chain termination and chemical degradation methods. The gene contained about 33.5 kilobases of DNA, including seven introns and eight exons within the coding and 3' noncoding regions of the gene. The eight exons code for a prepro leader sequence and 415 amino acids that make up the mature protein circulating in plasma. The intervening sequences range in size from 188 to 9473 nucleotides and contain four Alu repetitive sequences, including one in intron A and three in intron F. A fifth Alu repetitive sequence was found immediately flanking the 3' end of the gene. A 50 base pair insert in intron A was found in a clone from one of the genomic libraries but was absent in clones from the other library. Intron A as well as the 3' noncoding region of the gene also contained alternating purine-pyrimidine sequences that provide potential left-handed helical DNA or Z-DNA structures for the gene. *KpnI* repetitive sequences were identified in intron D and the region flanking the 5' end of the gene. The 5' flanking region also contained a 1.9-kb *HindIII* subfamily repeat. The seven introns in the gene for factor IX were located in essentially the same position as the seven introns in the gene for human protein C, while the first three were found in positions identical with those in the gene for human prothrombin.

Factor IX (antihemophilic factor B) is a vitamin K dependent plasma protein that participates in the middle phase of blood coagulation (Hedner & Davie, 1982). It is a single-chain glycoprotein that circulates in the blood as a zymogen to a serine protease. When blood coagulation is initiated following vascular damage, it is converted to factor IX_a, a serine protease that activates factor X in the presence of factor VIII_a, calcium ions, and phospholipid. Factor IX contains 12 γ -carboxyglutamic acid residues and one residue of β -hydroxyaspartic acid in the amino-terminal region of the protein. The γ -carboxyglutamic acid residues are involved in calcium binding to the protein, while the function of the β -hydroxyaspartate has not been defined.

Studies from our laboratory (Kurachi & Davie, 1982) and those of others (Choo et al., 1982; Jaye et al., 1983; Jagadeeswaran et al., 1984) have led to the isolation and characterization of a cDNA coding for human and bovine factor IX.

More recently, Davie et al. (1983) and Anson et al. (1984) have reported the isolation and partial characterization of the gene for human factor IX, which is located on the distal region of the long arm of the X chromosome (Chance et al., 1983; Boyd et al., 1984; Camerino et al., 1984). In the present investigation, we report the entire nucleotide sequence of the gene for human factor IX, which was isolated from two different λ phage genomic libraries. These studies establish the size and location of eight exons and seven introns present in the coding and 3' noncoding region of the gene for this blood coagulation factor and the presence of a number of repetitive

DNA sequences within and immediately flanking the gene. These studies also provide a basis for comparing the structure of the normal gene with abnormal genes that occur about once in every 40 000 males (Hedner & Davie, 1982).

EXPERIMENTAL PROCEDURES

Materials. DNA restriction endonucleases were purchased from Bethesda Research Laboratories, from New England Biolabs, or from Amersham. T4 polynucleotide kinase, *Escherichia coli* DNA polymerase I, the large fragment of DNA polymerase I (Klenow fragment), bacterial alkaline phosphatase, T4 DNA ligase, nuclease Bal 31, and nuclease S1 were obtained from Bethesda Research Laboratories. Exonuclease III (*E. coli*) was purchased from New England Biolabs, and ³²P-labeled deoxynucleotides or derivatives were purchased from New England Nuclear. [³⁵S]dATP α S was obtained from Amersham, and M13mp8 and -mp9 were products of Bethesda Research Laboratories. M13mp10, -mp11, -mp18, and -mp19 were purchased from Pharmacia P-L Biochemicals, and bacteriophage λ EMBL3 DNA was obtained from Promega Biotech. The λ in vitro packaging extracts were purchased from Amersham, while the universal sequencing primers (pentadecamer or heptadecamer) were obtained from New England Biolabs. Deoxyribonucleotide triphosphate and dideoxyribonucleotide triphosphate were products from Pharmacia P-L Biochemicals. The genomic DNA prepared from human fibroblast cells (49, XXXXX) originally established by Dr. S. Funderbuck at the University of California, Los Angeles, was kindly provided by Dr. S. M. Gartler in the Department of Genetics of this University.

Construction of a Genomic DNA Library in Bacteriophage λ EMBL3. Genomic DNA (about 150 μ g) prepared from cultured human fibroblast cells with 5X chromosomes (49,

[†] This work was supported in part by Research Grants HL 31511 and HL 16919 and Training Grants HL 07147, GM 07270, and AG 00057 from the National Institutes of Health.

[‡] Present address: Eisai Co., Ltd., Tsukuba Research Laboratory, 1-3, Tokodai 5-chome, Toyosato-machi, Tsukuba-gun Ibaraki 300-26, Japan.

XXXXX) was digested overnight with *EcoRI* and subjected to size fractionation by electrophoresis in 0.5% agarose gel. The region of the gel containing DNA fragments of about 12–14 kb was removed and the DNA recovered by electrophoresis of the gel in dialysis tubing. The DNA fragments were then extracted twice with phenol/chloroform, precipitated with ethanol, and then dissolved in 10 mM Tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl)/0.1 mM ethylenediaminetetraacetic acid (EDTA), pH 8.0.

The *EcoRI* arms of bacteriophage λ EMBL3 (Frischauf et al., 1983) were prepared by digesting phage DNA with *EcoRI* followed by purification by electrophoresis in a 0.5% agarose gel. The genomic DNA fragments (1.5 μ g) prepared as described above were ligated overnight at 14 °C to *EcoRI* arms (6.4 μ g) of λ EMBL3 with 6 units of T4 DNA ligase in a final volume of 30 μ L. The ligated mixture was then subjected to an in vitro packaging reaction and used for infecting *E. coli* strain Q359 according to the manufacturer's instructions (Amersham). Approximately 7×10^5 plaque-forming units (pfu) of recombinant phage were obtained and designated as the 5X genomic library. This library was screened for clones for the 5' end of the gene for factor IX without amplification.

Screening of Genomic Libraries. The λ Charon 4A genomic DNA library (Maniatis et al., 1978) containing about 9×10^6 pfu was grown in *E. coli* (strain LE392) and screened for genomic clones for factor IX by the plaque hybridization procedure of Benton & Davis (1977) as modified by Woo (1979). The cDNA coding for human factor IX (Kurachi & Davie, 1982) was employed as a hybridization probe and was radiolabeled to about 3×10^8 cpm/ μ g by nick translation (Rigby et al., 1977) in the presence of all four radioactive deoxynucleotides, [α - 32 P]dNTP.

A DNA fragment (76 bp in size) was prepared from the 5' end of the factor IX cDNA by cleavage of pHfIX1 (Kurachi & Davie, 1982) with *PstI*, *RsaI*, and *HhaI*, and a genomic DNA fragment (nucleotides 4750–5740 in Figure 3) was prepared from FIX λ 61 clone with *EcoRI* and *PvuII* digestion as specific probes to screen the 5X genomic library for the 5' end of the gene for factor IX. The hybridization procedure employing nitrocellulose filters with recombinant phage DNA was carried out overnight with the radiolabeled probe (routinely about 1×10^6 cpm/mL) in 6 $\times$ SSC (0.09 M sodium citrate, 0.9 M NaCl, pH 7.2) containing 2 $\times$ Denhardt's solution (0.04% ficoll, 0.04% poly(vinylpyrrolidone), and 0.04% bovine serum albumin), 0.5% sodium dodecyl sulfate (SDS), and 1 mM EDTA at 68 °C. The filters were then washed 2 times for 1 h in 6 $\times$ SSC containing 0.5% SDS at 68 °C. Phage clones with positive signals were then plaque purified. The purified phage was then amplified either by a plate-lysis method (Maniatis et al., 1982) as modified by Chung (1983) or by a liquid culture lysis method as described by Silhavy et al. (1984). The genomic DNA inserts in the purified phage were then cut with *EcoRI* and subcloned into pBR322 or into an M13 phage DNA vector for sequencing. In order to obtain overlapping DNA fragments for sequencing, the DNA inserts were also cleaved with *BglII* alone, *BglII* and *BamHI*, or *PvuII* alone, and these fragments were subcloned into pBR322 at the *BamHI* site or the *SmaI* site of a derivative of pBR322.

DNA Sequence Analysis. DNA sequence was determined initially by the chemical degradation method of Maxam & Gilbert (1980). Most of the exons and splice junctions and a number of short stretches of sequence of introns were sequenced by this method and confirmed later by dideoxy chain termination method. Essentially all of the sequence was also determined by the dideoxy chain termination method developed by Sanger et al. (1977) employing the M13 phage cloning

and sequencing system of Messing et al. (1981) and Norrander et al. (1983). The dideoxy sequencing methods employing nuclease Bal 31 and exonuclease III as described by Poncz et al. (1982), Guo & Wu (1983), and Henikoff (1984) were also extensively employed. A typical sequential digestion of DNA fragment with nuclease Bal 31 was carried out as follows: 100 μ g of plasmid pBR322 containing a 6.8-kb insert DNA at the *EcoRI* site was linearized by *SmaI* and then incubated with nuclease Bal 31 (25 units (100 μ g of DNA) $^{-1}$ mL $^{-1}$) in 1 $\times$ Bal 31 buffer (20 mM Tris-HCl, 12 mM MgCl₂, 12 mM CaCl₂, 1 mM EDTA, 40 mM NaCl, pH 8.0) at 30 °C. Aliquots were removed every 3 min over a period of 30 min. In this experiment, about 150 bases were removed per end per minute. Each aliquot was immediately extracted with phenol/chloroform and the DNA fragment recovered by ethanol precipitation. The DNA was then digested with *EcoRI* and subjected to electrophoresis on a low melting point agarose gel (0.7%). The DNA fragments that were systematically shortened from one end were eluted from the gel, and each was ligated to the replicative form of M13mp18 previously cleaved with *EcoRI* and *SmaI*. An aliquot of the ligation mixture was then used to transform competent cells of *E. coli* JM103 in the presence of 50 mM CaCl₂. The transfection of the competent cells, isolation of single-stranded M13 phage DNA, and sequencing of the DNA were carried out as described in the Amersham sequencing handbook.

A typical sequential digestion of a DNA fragment with exonuclease III was carried out as follows: about 90 μ g of plasmid DNA containing an 8-kb insert between the *BamHI* and *EcoRI* sites was linearized with *HindIII* and incubated with exonuclease III (1500 units/90 μ g) in 0.26 mL of 1 $\times$ exonuclease buffer (66 mM Tris-HCl, 6.6 mM MgCl₂, 20 mM NaCl, and 1 mM dithiothreitol, pH 8.0). Under these conditions, the DNA fragment was sequentially deleted on one strand at the 3' end at a rate of about 400 bases per minute per end. Aliquots were removed every 30 s over the next 10 min and immediately mixed with 10 volumes of 1 $\times$ S1 nuclease buffer (30 mM potassium acetate, 0.25 M NaCl, 1 mM zinc acetate, and 5% glycerol, pH 5.0). S1 nuclease was then added to each aliquot (10 units/100 μ L of reaction volume) and the incubation continued for 10 min at 37 °C. The reaction was terminated by the addition of 1:1 phenol/chloroform. The DNA was precipitated with ethanol, dissolved in 20 mM Tris-HCl, pH 8.0, containing 10 mM MgCl₂ and four deoxynucleotides (0.2 mM), and incubated with the Klenow fragment (1 unit/10 μ L of reaction mixture). The blunt-ended DNA was then digested with *EcoRI* and *BamHI*, and the digests were subjected to electrophoresis on a low melting point agarose gel (1%). The DNA fragments of interest that were sequentially deleted at the 3' end were recovered and ligated to an appropriate vector as described above.

Often the replicative form of M13 containing a DNA insert to be sequenced was further subjected to exonuclease III digestion as follows: 10 μ g of M13mp19 DNA with an insert in the *AccI* site was cleaved with both *KpnI* and *BamHI* and treated with exonuclease III (150 units/10 μ g) in 50 μ L of reaction mixture. The DNA that was sequentially deleted at *BamHI* was blunt ended with S1 nuclease and polymerase I (Klenow fragment), self-ligated, and used directly to transfect *E. coli* JM103 as described by Henikoff (1984). Often, the size of the insert in the single-stranded DNA template in M13 was estimated by subjecting aliquots of template DNA to 0.5% agarose gel electrophoresis with the appropriate M13 single-stranded template(s) of known insert size. Sequencing reactions with either [α - 32 P]dATP or [35 S]dATP α S were carried out essentially according to the sequencing manual provided




FIGURE 1: *EcoRI*-*TaqI* restriction map of the genomic DNA inserts in five different λ phage clones containing the gene for human factor IX. The locations of each of the eight exons and the five Alu sequences are shown with solid bars and solid arrows, respectively.




FIGURE 2: Detailed restriction map and sequencing strategy for the gene for human factor IX. The locations of each of the eight exons and the five Alu sequences are shown with solid bars and solid arrows, respectively. The *EcoRI* sites are numbered 1–13. The length and direction of the sequencing by the dideoxy chain termination method are shown by the thin arrows. Arrows with a small vertical bar indicate that DNA sequencing started at a specific restriction site, while arrows lacking the vertical bar indicate that DNA sequencing was started at a site that was generated by sequential digestion employing endonuclease *Bal* 31 or exonuclease III. Regions that were sequenced by the chemical degradation method are not shown. The nucleotides are listed in kilobases from 0 to 42. Approximately 90% of the first 4 kilobases was sequenced, but the sequencing strategy is not shown.

by Amersham. The reaction mixtures were then applied to a 6% polyacrylamide sequencing gel formed with a buffer gradient as described by Biggin et al. (1983) and run at 2000

V for about 2.5 h. The gel was then dried and exposed overnight to X-ray film (Kodak XRP1). When [^{35}S]dATP α S was used, the polyacrylamide gel was submerged with 10%

GTATATCTAG AAAACCCCAT TGTCTCATTC CAAAATCACC TTAAGATGGA TAGGCAACTT CAGCAAAGTC TCAGGATAAC AAAATCAATG TGCAAAAATC -2866
 ACAGGCATTG TTATACACCA ATGAGCAGCA AACAGACAGC CAAATCATGA GTGCAACTCC ATTCACAATG GCTTCAAGA GAATAAAAAT CCTGAATATC -2766
 CTACTTACAA GGGATGTGAA GGAGCTCTTC AAGGAGAACT ACAACCACTG GCTCAATGAA ATACAAACAA ATGGAAGAAC ATTCATGCTC -2666
 CATGGGTAGG AAGAATCAAT ATCATGAAAA TGGCCATAAT GCCCAAGGTA ATTTATAGAT TCAATGCCAT CCCCATCAAG CTACCAATGA CTTTCTTCAC -2566
 AGAATTTGAA TAAACTACTT TAAAGTTTAT ATGGAACCAA AAAAGAGCCC GCATCGCCAA GTCAATCCTA AGCCAAAAGG ACAAGCTGG AGGCATCATG -2466
 CTACCTGACT TCAACTACTA CTACAGGCTC ACAGTAACCA AAAACGACAT GTACTGGTCA CAAAACAGAG ATACAGACCA ATGGAACAGA ACAGAGCCCT -2366
 CAGAAATGAT GCCACATATC TACAACATCT TGATCTTTGA AAAACCTGAC CTTTCAACAA AATGGGGAAA GGAATCCCTA ATTAATAAAT GGTGCTGGGA -2266
 AAATCTGAAT GCCATATGTA AGAAGCTGAA ACTGGATCCC TTCTTTATAC CTATATACAA AATTAUATTA AGATGGATTA AAGACTTCAT TGTGTAGCCT -2166
 AAAACCATAA AAAACCTAGA AGAAAACCTA GGCAATACCA TTCAGGACAT AGGCATGGGC TTTGACTTCA TGCTCTAAAC ACCAAAAGCA ATGGCAACAA -2066
 AAGCCAAATG TGACAAATGG GATCAAAATGA AACTAAAGAG CTCTGCACAA GCAAAAGAAA CTACCATCAG AGTGAACAGG CAACCTAAAG AATGGGAGAA -1966
 AATTTTGTGA ATCTACTCAT CTGTCCAAAG GCTAATATCT AGAATCTAAA ATGAATCTAA ACAAAATTAAC AGAAAAAACC ATCAACAAAT -1866
 GGGTGAAGGA TATGAACAGA CACTTCTCAA AAGAAGACAT TTATGCAGCC AACAGACACA TGAAAAATATG CTCAGCATCA CCGGCCATCA GAGAAATGCA -1766
 AATCAAAACC ACAATGAGAT ACCATCTCAC ACAAGTTAGA ATGGCGATCA TCAAAAACAT AGGAAGCAAC AGGTGCTGGA GAGGATGTGG AGAAATAGGA -1666
 ACACCTTGAC ACTGTTGGTG GGACTGTAAA CTAGTTCAAC CATTGTGGAA GTCACTGTGG CGATCTCTCA GGGATCTAGA CCTAGAAATA CCATCTGACC -1566
 CAGCCATCCC ATTTATGGGT ATATACAAA GTATTATAAA TATAGTGTCT ATAAAGACAC ATGCACACGT ATGTTTATTG CGGCACCTTT CACAATAGCA -1466
 ATGACTTTGA ACCAACCCAA ATGTCCAAAC ATGATAGAAT GGATTAAAGAA AATGTGGCAC ATATACACCT AGGAATACTA TGGAGCCATA AAAAAGAAAT -1366
 GAGTTCTAGT CCTTTGTAGG GCATGGATGA AGCTAGAAAC CATCATCTCT AGCAAACTAT CGCAAGGACA AAAAACCAAA CACCGCATGT TCTCACTCAT -1266
 AGGTGGGAAC TGAACATGA GCATCTTGG ACACAGGAAG GCGAACATCA CACACCGGGG CTCTGTTTGG GGTGGGGGGG GAGGGGAGGG ATAGCATTAG -1166
 GGGATATACC TAATGCTAAA TGACGAGTTA ATGGGTACAG CACACCAACA TGGCAGATGT ATACATATGT ATACAAACCTG CTGTTGTGGG ACATGTTAGC -1066
 TAAACCTTAA AGTATAATAA TAAAAAAGAG ATCATTCTAA AATTTATACA AGCCCTTAGA ACAGTTAAAA ATATCTTACC AAAAGAGAAA TAAAGTTTGA -966
 GGAATCAGTC TACCTAATAT AAGCTCTTAC TACATAGCTA GAGTTAATAT TATTGGCAGA GGGATAAATA CATCAATGGC CACAAAGAAAT -866
 GATAGAGAAA CTGGAAGTAG ACCCAAAACA ATATGGTTAA CTGACTTACG AAAAATTTCT AGAAGCCATT CAGTCGAGGA AGGATAGGGT GGTATTGTTG -766
 TTTTGTGTTT TAAACAAATG TGTGGATATA ATTGGACATA CATTGTGAAA AAAAAATGAA GTTTGACCTA AACATCATAC TTTACACAAA TATTAACCTA -666
 AAATGGAGCA TGGGCATAAA TCTAAACCTT CAAACTGTAA AACTATTAGA AAAAAATAGG AAAAAAACA TGTGTAGTCTA GTTGTAGTGG AATGATTCTA -566
 AATGTGATCC ATAAACAAA AACAAATAAA CTGGACTACA TCAAAACTMA AAAAACTTAC TCTGTGAAAG ACCTAATTAAG GAGGACAAAA GACAGGCTAC -466
 AGGCTGGAGA CAATATATAT AATCCACGTA TCTATGAAAG GAGTTAATAT TAAAGATCTGA AAGAATCTGA CAGTAAAAAA CACAAAGCTAG -366
 ACTAAGTGA CCACTCATAC ATTGCTGATG GAAATGTAAA GTGGTACAGC CATTTTGGTA AACATCATTG CTCTCTGACA AAGATACGGT GGGTCCACTG -266
 GATGAACCTG GCTGCCACAG TAAATGTAGC CACTATGCCT ATCTCCACTT TGAAGATGTG TCACCTCTCG TTTGAGACTC AATCAGCCCA CAGTGGCAGA -166
 AGCCAGAGTA ATCAGAGGTG AATTTAATA ATGACCACATG CCTTCTCTCT TCATTGTGTC CAAGAGGCCA TTGGAATATG TGGAAATAGC -66

-46

Met

GATGGACATT ATTTCCAGAG AGTAAATACA GCTCAGCTTG TACTTTGGTA CAACTAATCG ACCTTACCAC TTTCACAATC TGCTAGCAAA GGTT ATG 32

Gln Arg Val Asn Met Ile Met Ala Glu Ser Pro Gly Leu Ile Thr Ile Cys Leu Leu Gly Tyr Leu Leu Ser Ala Glu Cys
 CAG CGC GTG AAC ATG ATC ATG GCA GAA TCA CCA GGC CTC ATC ACC ATC TGC CTT TTA GGA TAT CTA CTC AGT GCT GAA TGT 113

Thr
 ACA G GTTT GTTTCCTTTT TTAAATATACA TTGAGTATGC TTGCCCTTTTA GATATAGAAA TATCTGATGC TGTCTTCTTC ACTAAATTTT GATTACATGA 211

TTTGACAGCA ATATTGAAGA GTCTAACAGC CAGCAGCGAG GTTGGTAAAGT ACTGGTCTCT TGTAGCTAG GTTTCCTTCT TCTTCATTTT TAAACCTAAA 311
 TAGATCGACA ATGCTTATGA TTCTAATAAC ACTGTTTCAGT TCATGATTTG GTCATGTAAT TCCTGTGTAGA CTTCTTGGTT 411
 TAAAAAATTT AAAAGTGGGA AAACAAAGAA ATAGCAGAAAT ATAGTAAAAA AAAATAACCA CATTATTTT GTTGGACTT ACCACTTTGA AATCAAAATG 511
 GGAAACAAAA GCACAAACAA TGGCCTTATT TACACAAAAA GTCTGATTTT AGATATATG ACATTTCAGT GTTTCAGAGG TATGTAATGA GGTGTGTCTC 611
 TAATTTTATA AATTATATAT CTCTCAATTA AAGTTTATAG TAAAAACATA AGATTAACCT TCCATTAGCA TATCACCAGA CTTTTCATG 711
 GATTAGGAAA AAATCATTTT GTCTCTATGT CAAACATCTT GGAGTTTGTAT TATTTGGGGA AACACAATA TCAGTTGAGT TCCCTAGGGG AGAAAAGCAA 811
 GCTTAAAGAT TGACATAAAG AGTAGGAAGT TAGCTAATGC AACATATATC AACATATATC TACACAACTA CAGTGACTTT ATGATTTTCC CAGAGGAAG 911
 CATACAGGGA AGAATTTATC CCATTTGGAC AAACAGCATG TTCTCACAGG AAGCATCTAT CACACTTACT TGTCAACTTT CTAGAATCAA ATCTAGTAGC 1011
 TGACAGTACC AGGATCAGGG GTGCCAACCC TAAGCACCCC CAGAAAGCTG ACTGGCCCTT TGGTCCCCAT TCCAGACATG ATGTCAGCTG TGAATTCAGA 1111
 CTGAAATGCT GAAATAACGA TAAAAAATAA TACAGAGGTT AAACAGTCAA AGTGAGTAAA GTCAAGGGAT AAGAAAAAAT TGTTCGAAAA CTCACAAAGC 1211
 AGGACATAAA GCAAGGCCAT TAGATATATC TCATTAGTGT GACATCTGGG AGGACAAAGC ATCCAAACCC TTTCTCTCAT ATAGTGGTG AGATGATGAA 1311
 GGTGTGAAGA GGCCTCTGCC AGTGTGAAGA CTCTGTGATG TGGGGAAGG ATAGATAAGA ATAGAGTAGA ACCTGGCTTT TGGAGCCTGG GAAATAATGA 1411
 CTAGCGATAA ACCTGAAGGG AAGTTAAGTA TACGATCCCC AGATAATACT AAGGAGAAAG GCAATGTGAT TCTGCAGCCA TTGTAGCCAG AGATAATAGT 1511
 CCCTTGAGGA AGGGGCCAGG GGAATTTTTC TAAGGATAGA CAGTATTAAT GCGACTCTCT CTCTGCTAT TAAACTCTCA TGGCTTCTA AAGGGATTT 1611
 CGGTGAGTGA TTTGCTGAGA TTTTGTGATT TTCTGCTGTC TGCTTTAGG TATTATTGCA AACAGTTTGG AATTTTGAAA TTTAAACAGT TCTGTAAAC 1711
 CAGTTTAGTT TTTGTAAGTG TATGATCAA AGATGTCTCT CATTACAGCA TTACTGAGTT TACTGAGTT TGGCAGGAT TGTGTCAAGG TACTAGGGGT 1811
 ATGGGGATAA ACCTGAGTCC CTCTTTGATG TAAAGCAGCA TGAGGCGAGG TACAGAGTTT CAATATATGT GATAAAATGT GCCTAGGTA TACTAGGATC 1911
 ATAGAGAAAG GAACACATTA AATGGGGAAG CAATTGATAG AGAGAGAATA TTTTCATCTG GGTCTTAAAA GATGAGTAGG CGTTCTCTCT CTTTAAATGT 2011
 CTGATATAAG GGCATTTTAT GCAAGAAGAG ATCACTCGTG CAAAGACTCA GCTTTGCAAG AACGTGAGG ATTTGAGGAG TTTTGTATG TTCCATATGG 2111
 ACTATGACAA GTGAGCAGG TAACTAGGC AGAGCTGGTC ATCAGATAAT GAAGTACATA ACCTAAGGAT ATTTGACAAT AATAGGATTA ATCAGGATG 2211
 CGAAGTATAA ACATAAGAGG TACCCTGAT GGCTGATTTA GGATGCCGAC TCTGGCAACA CGCTAATGAA ATGATAGTGG GGGAGGGGGG CTGACCAAGA 2311
 CAGTAGGATA GCGATCTGGA GTTATCTGCG AGGAGACATA GAGAGACATA TCTGAGTAA GAGTCTTGGG GACTTTGTGT TTGATGTGAT TATGGACCA 2411
 ATATTAGAGA AGTAGAAGTG GTGCTCTTTA GTCTGACTGC CAGAGCTGTA ATCTTGAATG TTTTAGTAGT TTACCTTGCA AGCCCTTAG CCTCATGAA 2511
 AGAATAATGT CTAAGAGAA CTCAATTTAA AACATAAGT ACAGTGCCCTA TCTCTGGGGA CTCTTGTGAG GATGAAGTGA GATAAGTTAC TCTGACAGT 2611
 TCTATCTTCC TCATTATATA TACATATAGA TTAGCTATTA CTGGCTTACG ATGAGTGAAG AGTTGGAGAG AATCTGAAAT TCCAGGAGAC 2711
 GTCCCAACACA CAGGAAGCAT TACATATAGA TTAGCTATTA CTGGCTTACG ATGAGTGAAG AGTTGGAGAG AATCTGAAAT TCCAGGAGAC 2811
 TATCTGACTA TAGGTGAGTA TTTGGAAGCT ATTTGTTCTGT AAGCACTAGT TACAGACAGT GTGTGGGAGT CTGGAGAGAG AGCATGGATA TTTGTATACC 2911
 TAGTACAGTG CCTGGCAGTA GTGGTTGTAT GCTCAGTAAA TTTTGTGAC TTTGCTTGTG ATGCTCTGTT TGGTCCACTC TTTGCTCAGC CTAGCAAGT ATATATAAGG 3011
 TATACTTTGA TGCCCCGAGA AGTGAAGGAG CTGTGAGCCG TGGGAGAACCC TGAGCATTTA AGGGCCATGG AGAGTAAACAG AGTTAATCA ATTCAGGTGC TGGATGGATA 3111
 TGAATAAGGA AAAAGCTGAG CTGTGAGGAG GGGAAACAGA ATAGAGTGAT TATTATAAAA AGAGTTTCTT AAAAAAGGAG AGATCAACAA TTAGAAATTA TTTAGAGCAG 3211
 ACAGGAGTTA GAGCAAAAGC GGGAAACAGA ATAGAGTGAT TATTATAAAA AGAGTTTCTT AAAAAAGGAG AGATCAACAA TTAGAAATTA TTTAGAGCAG 3311
 CCAGTAAATA CATAAATCA AAATTATCTT TTAGGTCATT CCTGATTTGT ACATATGTCA TTTCAATATA TAAATGTGAT TAAAGGAAGA AAAGAGCTAC 3411
 ACAGAAGTTA TTAAGAGCT TAAAGAGATT GAGAAATTTA AAACAGAAGA AAGTAGGGCC AACATGAAAG GAGTAGGGAG AAAAGAGAT AACAGGATA 3511
 TTGTCTCACT GATCCTGCCA ACACCTGTGA GATAGATATT CTTATTATAC TACTGTTAA CCTAATTTAC ATTTGACAAA GTTAAGGTTT AGAGCTTTGT 3611
 TGACTTTGCC AAGGTACAGG GTCTAGAGGA GGCAGATACT TGATTCAAAC CTATTCTCTG CTGACTGTAT TCTAAAGTCT TCTAAAGTCT TCAACACAC 3711
 TGTACAGTCA GCTCTCTTGT TGAGTTCCAC AGCCACAGAT TCAATTAACT CAAGACTAAA ATATATTCAAG AATAGTTCAAG ATGGTTCCAT CTCTACTGAA 3811
 CATGTACAGA CTCCTTTATC TTTCAATTAT CCCTAAACAA TACAGCATAA CAACTATTTA CATAGCATTT ACATTGTATT AGCTATTAA AGAAACCTAG 3911
 AGATGATTTA AAGTACAAAG GAGGATGTGT TTAGGTTATA TCGAAATAGT AAGCCATTTT TATATCGGAG ACTTGGAGAT CCACAGATCT TGTATTGTTG 4011
 AGGGGGTCTT GCCACCAATT TTCCATGGAT ACTGAGGAAC GACTGTAAAT GAGTGCAGG GTGATGCTA TTTAGGAGTG TCCAGGGCCA AGTAAATGAG 4111
 TTGCTGAGCA GAGAGGTGGG TGAGGCTGTG GAGGCATCAA TATGTGGTGG CATCTACTG ATTTTGTGGT CTTTGTGGT TCCAGCTCT CCGCTGTCT 4211
 GGGAGAGAAA GGAATGAAGC AGAGGCTGTC TCCAATTTAG GGGCTAGGAT TCGAGGTTGG GCACAGCAT GCAAAACAGT GAAGGAAAT GAGAAATATG 4311
 GCCAATGAAG AGTTGAAGAG TGGTGGCTCA CACCTATAAT CCGAGGCTTC TCAGAGGCCC AGGCAGGCAG ATCACTTAGG ATCAGGAGTT 4411

CGACACCAGC CTGGCCAACA AGGTGAAATG GTGAACCCC GGCTTTACTA AAAATACAAA AATTAGCTGG GCATGGTGGC GGGTGGCTGT AATCCAGCT 4511

ACTTGGGAGG CTGAGGCGAG AGAATAGCTT GAACCTGGGA GATGGAGGTT GCAGTGAGCT GAGATCGCAC CACTGCACTC CAGCTGGGC GACAGAGCAA 4611

GACCTCTGCA AAAAAAAG AGTTGAAGAG AAAAGTCTTA GGCTAAATTC AAGAAAAAAA AGTGAGGCCA AAGGAACTT CGACAGCAAG GGAAGAGCAG 4711

GGATGTCAAG GGACTAGAAC ACTCCATAAA GTGAACAGCT GCAATGAAA TAAGGGAAGA AAGTTTAGTT CATCTCCGTT TCTTCTCTTT CTTTCTTACT 4811

TTCTCTTCTC TTCTTTTGTG GAGGTAGTCA GGAAGTAGTC CAGAAATACC ATCTTATAAG CCCTTGGTCC TCTTGTAGT TCTTGTAGT GATTCAGATA 4911

TATTTGCTAGA CCTTTGAAGA AAGGACAAC TCCAGGCCAT TCTTGTAGCT CTGTTTATTA ATTTTATACA TACACACACA TATATGTATA TACATGAAAA 5011

CACACAAACA CATGTGTGTG TACACAGCCA TGCATTCCCT ACAAATGGGG ATATATTCTG AGAAATGTGT CATTAAGCAA TTTTCATCAT GTGGCAAGAT 5111

AATAGAGTGT ACTTACCTAA ACCTAAATGG TATAGCTTAC TACATACCTA GGTGTGATTG ATGTGGCCTA TTGCTCTGAT GCTTCTGGG GCTTCTGGG 5211

TACAGCATGT GACTGTACTG AACCTGTAG GCAATGGTAA CACTGGTATT TGGTATCTA ACATACAGAA AGGTACAGT TGAATACCT ATTTAACC 5311

TATGGGACCA CTGTGCTATA ATGTGGTACA TCAATTGACCA AAATGTCAAT GTGCAGCAAA TGATTATCTC ATATATATAT ATATATGATA TGAATATAT 5411

GATATATATG TGTGTGATA TATGTATACA TATATATGT TACATATATG TATACATATA TACACACACA TATATATGTA CACACATATA TGTATATATA 5511

TGTACAGCA TATATGTATA TATGTGTACA CACATATATG TATATATATA TGTACACACA TATATGTATA CACACACACA CATAGAGAGA 5611

GAGAGAGAGA AGAGGAGAGG AAGGAGGAG GGAAGGAGAA ATATGATTTA GATAGAGACA TCTATCTCTC AGAGTTGAGG AGTGTCTCTT CAGACTAGGT 5711

AGATGTAGCT	TAAAAAAAC	ATATCCTGGA	ATTCTAGAGA	GATGCTTAAA	TCACTGCAAT	TCCTATAACA	CTTGCCAACC	AAAGGTGCTG	TTGATCTGAA	5811
ATTGCTTTT	TAAATTAATG	CAGTGATTTT	TCTTTAACAT	CTAGTGACAG	ACACTGGGGT	CACATTTGCA	GCTGGACCAT	AATTAGGCTT	CTGTCTTCA	5911
GGAGACATT	GTTCAAAGTC	ATTTGGGCAA	CCATATTCTG	AAAAACAGCC	AGCCAGGGTG	ATGGATCACT	TTGCAAAGAT	CCTCAATGAG	CTATTTTCAA	6011
GTGATGACAA	AGTGTGAAGT	TAACCGCTCA	ATTTGAGTTC	TTTCTTTTTT	ATCCAAAGTA	AATTCAAATA	TGATTAGAAA	TCTGACCTTT	TATTACTGGA	6111
ATTCTCTTGA	CTAAAAGTAA	AATTGAATTT	TAATTCCTAA	ATCTCCATGT	GTATACAGTA	CTGTGGGAAC	ATCACAGATT	TTGGCTCCAT	GCCCTAAAGA	6211
GAAATTGGCT	TTGAGATTAT	TTGGATTAAA	AACAAAGACT	TTCTTAAGAG	ATGTAAATTT	TTCTCATGAT	TTTCTTTTTT	GCTAAAACTA	AAGAATTATT	6311
-17										
Val Phe Leu Asp His Glu Asn Ala Asn Lys Ile Leu Asn Arg Pro Lys Arg Tyr Asn Ser Gly Lys Leu										
CTTTTACATT	TCAG	TT	TTT	CTT	GAT	CAT	GAA	AAC	GCC	6393
AAT AAC AAA ATT CTG AAT CGG CCA AAG AGG TAT AAT TCA GGT AAA TTG										
-1 +1										
Glu Glu Phe Val Gln Gly Asn Leu Glu Arg Glu	Cys Met Glu Glu Lys Cys Ser Phe Glu Glu Ala Arg Glu Val Phe Glu									
GAA GAG TTT	GTT CAA	GGG AAC	CTT GAG	AGA GAA	TGT ATG	GAA GAA	AAG TGT	AGT TTT	GAA GAA	6474
GCA GCA CGA GAA GTT TTT GAA										
38										
Asn Thr Glu Arg Thr	AAC ACT GAA AGA ACA G T									
AAC ACT GAA	AGA ACA	G	TGAGTATTTC	CACATAATAC	CCTTCAGATG	CAGAGCATAG	AATAGAAAAT	CTTTAAAAAG	ACACTTCTCT	6570
TAAATTTT										
39										
AAAGCATCCA	TATATATTTA	TGTATGTTAA	ATGTTATAAA	AGATAGGAAA	TCAATACCAA	AACACTTTAG	ATATTACCGT	TAATTTGTCT	TCTTTTATTC	6670
46										
Thr Glu Phe Trp Lys Gln Tyr Val	TTTATAG ACT GAA TTT TGG AAG CAG TAT GTT G G									
TTTATAG ACT	GAA TTT	TGG AAG	CAG TAT	GTT G	G	TAAGCAATTC	ATTTTATCCT	CTAGCTAATA	TATGAAACAT	6763
ATGAGAATTA TGTGGGTTTT										
47										
TTCTCTGCAT	AAATAGATAA	TATATTAAC	TTTGTCAAAA	GGACTCAGAA	AGATCAGTCC	AACCCCTCTAA	CCCATATTGG	ATGGTGATAT	ACTACAGGGT	6863
TATGCCAGTG	TGGGAACAT	CGCTGGTAAA	TAAGTTTAAAT	CCTCCCTAGG	GCTTCACAAA	GAACATTTGT	CCACCCAGG	AGGGTGGAA	GAAGAACTG	6963
AAATGATTGT	GTCTTAGAAC	CTAATGAAAG	TTTGCATAAT	TCAGTAAAT	CAGAGACTGC	TGATTGACTT	AAATGTTTAT	AGCTTCAAAG	TCCCTCTCAT	7063
TATCATGGCC	CAGAAGCCCT	TCCATGATTG	TCCCTCCCCA	CCCTCCCAT	TACCTTCTCT	GCCTCCTCTG	CTACTTCTCT	CCTCGCACAC	TGGGCTCCAG	7163
CCACCTCTGC	CTTCTGTGCA	CTTCTTGAC	ACTCTAGGAA	TGCTCCCAT	TTGGAGGGTG	TATCTTGCTG	TTTCTCTTAT	TTGGCTGTTC	CCAACTTCTT	7263
GTGGGCTGAC	TCCCTGAGCT	CCTTCGGGTC	TTTGCCCAAA	TGTTACCAC	TTAATGAGGC	CTACCTTTCAC	CATCTATATA	TACTTCAACC	TGCCCACTGA	7363
GCCTTACCAC	TCTAGACACC	TGTACAGAAC	TCCACTCTAC	TTTTTAAACG	AGCTTTTTCAC	CATCTAATGT	ATCATATAAT	TTCTTACTCA	TACTATTAT	7463
CATTTATTTT	CTCCTACTCC	ACTAAAATGC	AAGTTTCTAT	TGCGAGGGA	TATTCATTTG	TTTTTCTTAT	TGATATATTC	CTAGCACCTA	GAACAGTATC	7563
TGGAAAAGAG	GTACTCAGTA	AATATTTATC	AAATGAATTG	ACCAAAAGAA	GGAAAACTCA	AAACTTTAAT	GACAACTAAC	TTTAAAGCTA	CAATAGCTTA	7663
AAATTCAGAG	TAGGATTTTG	AGGGAGGGTA	AGTTTCAAAG	ATTGACTTAC	TGAAGACTAT	CTGCAATAAT	AAAAAGAAAT	TAACTCCAGC	AACAAATTTA	7763
CCAACTTCCA	TCAATTTGGA	ATCCAAATCT	ATTTTCTACA	GTTTATGTTT	CTGAGACACT	ACTGGACACT	CTTTTACTCT	CATAACTCAT	AACCTCTCCA	7863
CTTTTGTGTT	TAAATCATGA	GAGAAAAAGA	GTTGACTCTG	TTATATTTGT	TTATCTACCT	TTCTTGTATC	TTAGAAACGA	ATACTACCAT	ACCAGCTTCT	7963
ACTGAGGTGC	CCCCTAAAGT	TAGTCCAAAT	AGGCTTTTGC	AATCTCCATT	CCCGCAGAA	TTAGAATTTT	GAATCAGAT	ATTTATTTCT	AAAAAGTAA	8063
CCATGCCGAT	TTTCCCACCC	AAAAAATTTT	TGACTATTAA	ACTCTACAAA	TCCCTTCTAT	GCTCATCTCC	CACCCCGAGG	ATCATATTTT	AAAGTTGGGC	8163
CCTTGCCCTT	TGGGTACACT	AGGTACACTG	TTTGCTATAC	CACAGGTATA	GCTATCTGGA	AAACATGGAG	GGTATTATTC	TGTTACTACT	GCTTCGTCAA	8263
CCAAAAATA	AAACAAACA	AGAACAAAAA	AGAAACAAAC	TCCCTGCCTC	TTTTTACTTG	CAGTCAAGGT	TCCTAACCC	TACAAAAATA	GCTTATGTTT	8363
CTTCTTGCAC	ATAGTAGAAA	CCCAAGCTTC	TCACTGCTGT	GCTATTCTGT	ACCATCAACT	CATCACATAA	AGAGCCTGGT	TGAAGAATGA	TTGTCCAACC	8463
ACATTACTAG	CATCTGTCAA	GACTTTCCAG	TTTCAAAAAG	GCCTTACACA	TTTAAACCTC	ACACCATCTC	TGTGACCAAA	GCATTATTA	CTCCATTTTA	8563
CAGGAGAGTA	AACTGAAGCT	TAGGGAAGTT	AAAAGAACTG	CCAAAGGCTC	CCCATGTTGG	GAGTCATGAA	CCCCAGAGA	GAAGCCAAAT	TCTCTGTCTG	8663
TCAACCCCTT	GCCTTCTACTA	TTTACCTCTA	GGGCTTCAA	ATCTAAATGC	AGTTTATCAT	TAAACAGGAA	CCTGGTAGTC	TTAAACAGGA	ATCTCTCACT	8763
TGGTAAGATC	TGTCTCTTGT	TTGATTTTGA	CCCCAAGTGT	CTATGGCTTT	GCTGTGAACC	AAAGTACACA	CAGCTTAGAA	ACCAAAAGAG	AACCAAACTG	8863
GGGATAAAAT	GACACTCATT	TTAACGACAT	GTCTCAGCAA	ATGAGTTTCT	GTGTAGCTGG	CTGAAAGCCC	AGACCCCTTC	AGTAAACAT	CCTGAATAAT	8963
TCACATTTGT	TGGTCTATAA	TATAAAGGGC	AAATGTAGCT	CATTTTTAGA	CCAGTTCTGA	ACATCAATAG	TAACAAACCA	GAGATAACCG	ATTTTGTGTT	9063
CATAGAAATG	GAACAAATTA	GAGTATCTGT	GCAAAAGCAT	ATCAGATCTA	GGAGCAGAGG	GGACAAGGTC	TAATTTTATA	ATAAGCAAA	TTTCCAGGGA	9163
GGGACTACTT	ATGATAAAGG	GATATTAGTC	TCTTAGTCAA	CGGAACCTGG	ATACACGCTT	CTGACAGAGA	AGAGGGAGAA	TAGGACAGAA	TCTACACACC	9263
AGATGTCAA	GAGATTGCTT	TTAAATAGC	ACTGATAATT	AGAAATTTCT	CAGTTTCTCC	CTTTTCTCTC	ATTTCTTTGAT	TCTTATTTCT	ATCTTTATCT	9363
CTTACTCCTT	TGTTTCTCAT	ATATTGAGTC	TTACAGATCA	AGCTCCCAT	TTTTTCTTCA	GGGGTATTTT	TCTAGTTCAA	AGTGCCTACC	ATCTCCCTTC	9463
TGGTTCATTT	CATCTCTTCT	TCCCAAGGCT	CCTTTAGAGT	TGTTGATATA	GGCAGAGCAC	TAAGAAACCA	GACTTAAAGA	TTCCCTCTCT	ATTTGACTT	9563
TTTCTCTTTC	ACCTTATCTC	TCTCTAGCTT	TCTTACCAT	CAGTGTCTTC	AAAGGCTTTC	AGATACACGG	TAAATGCAGA	AACTTCAAGA	AAGGCAGAA	9663
GGAAACATAA	CCAATGCATA	CATAAATAA	GCACACTGTA	GAATCTTTT	AAATTTCTGA	TGATATATCG	AATGCTGTCT	CTCACATTAC	CTAGACCAT	9763
TGAAACCGAA	TTTGTAAAC	ATAGACTATC	TTTAAAGTAG	ACACAGATCT	TCTGACATGT	TTTCTATTGT	CTTGAACCAT	TACTGCATAT	GATACATCAA	9863
AGTTAAGTGA	CAATACAGAA	AAGCAGATTC	ATTTGTCTCC	TGCTTAGGCC	TGCTGTTCTC	AAAGTGGAAA	CGCCATATAT	TATCTAGCTC	AGTTTGTCTC	9963
ACAAGACCTG	CAATAGAGCC	TTGTGTGACA	TAGAGATAAT	ATTTGTTGAA	GCAATTAATA	TTGACTTGGG	ATTAACCTCT	CCATCATTTCT	ATAAGGAAGG	10063
ATTGAAATCT	CTTCTCACCC	TGTGCTGATA	TAGTACCTTT	ATATCAAAA	AGCTCTTCT	CCCTCTTCCC	TTGGATTGCA	TAAACTATGT	ACATGCTTTC	10163
CTCAGGGGCA	CTTTCTAGG	ACAGTGTGAG	CCTAAGGATC	TTTGTTTGGG	TGGCTTTTAG	AAACTCAGGA	AGACAGGAGC	ATCATATGCC	TATAGGCAGC	10263
TGGCTTCCAG	GTCAGTAGTT	TTGCTCTGAC	CCTAAAAATCA	GACTCCCATC	CCAATGAGTA	TCTACAGGGG	AGGACCGGGC	ATTCTAAGCA	GTTTACGTGC	10363
47										
Asp Gly Asp Gln Cys Glu Ser Asn Pro Cys Leu Asn Gly Gly Ser Cys Lys Asp Asp Ile										
CAATTCAAAT	TCTTAACCTA	TCTCAAAG	AT	GGA	GAT	CAG	TGT	GAG	TCC	10450
AAT CCA TGT TTA AAT GGC GGC AGT TGC AAG GAT GAC ATT										
84										
Asn Ser Tyr Glu Cys Trp Cys Pro Phe Gly Phe	Glu Gly Lys Asn Cys Glu Leu									
AAT TCC TAT	GAA TGT	TGG TGT	CTT CTT	GGA TTT	GAA GGA	AAG AAT	CYT GAT	GAA TTA	G GT	10537
84										
AAAGTTTCCC	TCTGAAACAA	GTTGAAACTG	GAAATGCAA	TATTGGTGTA	TCATAATTTT	TCTTAAAAAC	ATACCTTTGA	TGCTTATAAA	CATTTTCATT	10637
GTAGTGATAG	TTTTCAGGAT	ATGAGTTCAA	GAAGCTACAT	TAAATCAAT	AACAATATTT	GGTAACTAAT	ATTAAGTAAT	AATGATGTTT	CGACTCACCT	10737
TATTAATCTT	TAATACAAAC	GTATGTGGTT	AGTACTATCA	TTATGCGCAT	TCTATTCAGA	TAGAAAAACC	GCAACTCCAA	CGGCCAAAAA	TTACAGAGGC	10837
ATAAATGGTT	TAGACAGGAC	TTAAACCTCA	GTGTGACCAA	AACCCATGCT	TCTAACTACT	ATATTCAAAA	CTCAGAGAAA	AACTAGACCA	GAAATTTGAA	10937
ATCATGACTA	AATTGCTATC	AACATAGGTG	AAAGTCAAT	AAGTACAGAA	CTGGAGTATG	ACTGGCCAAT	TATCCCATAT	AATGGGAAT	CTCCACATGT	11037
ACAAACCACT	TCATATGCTA	AACCTGTTGA	CAACATTTCA	AGCTCATCCC	TGAATTTGAC	TATATTGATT	ACATCGAAAA	TGTTTACATG	CAACCTTAGA	11137
ATCCTTGTGT	ACCTTTTCTT	CTCAAGCCCT	AGATTATTTT	TTTTTCCGAC	GTTTTCAGTA	ATTGGAGCAG	TAAACCCAG	TGTCCTTAC	CTACTTGTTC	11237
ATTACCTCCA	GATGCAATAT	TACTGGTACT	GTGATTGAGA	AACGCACACA	GTGCTAATGA	GGAAATTCAT	TTCTACTCTG	ACACTCTGGA	AGAATAGAGA	11337
TGCAATCCTA	AGGAAGAAAT	TAAACACACA	GGCTACATGA	CTAAGGATAA	AGAGTAGAAA	ATTAGCAGGA	CTCTATTAAC	CGATTACAGC	AATCCACCTG	11437
ACAGATGAAA	AAGGCATGAA	ATGAAATGAA	ATGTAGCAGC	TACACTCTGC	CTATTGAGAA	AGGAAAAAAG	TCACCTGTAA	TGTTGTTGAC	AAATCCTTTC	11537
AGTACTAAAA	AATTCATGGA	CCATCTTCTC	TTAGTCTCGA	AAATTTCTTA	GAAAGTAAAA	AAAGGAAAG	GTGACAGGGC	AAAGACATTT	GAAAAAGAA	11637
AAAAGAGTGA	ATGAACCTGC	ACACCTGGCT	TGGAATCCCT	ATTCCTCTTA	GGTTTCCATT	GTGGGGGACA	AACTAATGCC	TGGGTTACCT	TTCTTGAGAG	11737
TGTGTTAAT	GATTCAATAT	CTCTGAAGTG	CTACTTTTCT	CTGAAAGGTT	ATAATTTGAA	ATTCAGATTT	ACCTGGATAA	ATTGATCTT	GCTATTATGG	11837
AAACCTCTAG	AAATCCTTGG	AGTATCTACT	CATTATCAGC	TTAAATAATA	TAGCCGGTGG	AGCTGAGGGA	ATGAGTAACT	CAATTATGCT	CAGTTACAACT	11937
TGAAGGGGAC	ATTGTTGTAA	ACTATAATTT	AAAAACATAA	TATCTTTACC	TAGTTTAAAA	AATAAAGATG	CTTTAAAGAG	AGGAAGGGAA	TAGCCCTGAG	12037
GAAATGTAAAT	ATAAGCACAA	AACCTCTACA	ACAGAGTTTG	CTACGTGTCT	GGCTGTGTTT	CACCCAGCAA	AAATGCTAAG	TCTACAACCT	ACCAACATCT	12137
GATAGTCTCA	TGTTCCCAAC	TTTGTGTTTG	GTCAGGCTG	TGCAAGTGTG	CTGAGGGCCA	CACCACCTCC	TGGCCTCTAC	AGTATATTGA	TCTGACCCAC	12237
CAATCTGATC	AAGGTTTAGA	AAAAATTTTT	CAGCCCAAGT	AGCTCACAAA	CAAAATGAGA	ATTGCCACAA	ATTGCTCTTT	ATCTCAGACA	ACAGAGGAAA	12337
GCTACGATCA	AAGCAATAAC	TAAATACCAT	TTAAGTTTGT	TGCTTCAAA	TAAAGACTAA	ATGCAACAGC	TACTAGATAG	CACAGTTTAT	GGGCTCATCT	12437
GGCCCAAGT	CTTTTGTCTT	ATAAGGTCTT	GAAAAAAGA	AAGGAGATTT	TCATCAATAA	GAGTTTTTTT	TTATCTTTT	CCCTTGTCTT	TACGGCCTTC	12537
CACCTGCGAG	GAGAGGTGTA	AACGTTCTAG	GCATGCAAT	TAGTTAAGA	ATATTAAATG	GCTATTGTTG	CCCTTGTGTT	AGAAATAAGA	CCTCTGTATG	12637
ATGTCCTAG	CTGTACATCA	AACCCCAATA	TCTCTCAGAT	AAATGAAGGT	CTGTAAGAA	TTGGTCATTC	CTGTCTCTTC	TAAAGAGTAA	CAGAGGCATT	12737
TTCCCGCAGT	AAAGTAGAAT	GGAAAAAGAA	CAAAAATCAC	AAGCCTATAA	ACACCTTCTT	CAATTTTCCC	AGCATGTAC	AGACACTACT	GTCTTATTTA	12837
CTACGATATT	CTGAGAGATA	AAAAAAAGAA	ATATGTTGAG	TTTAGCTGAA	CACAGCATGA	TTTGTGGTGA	AACTTGTATA	ATAAAACACT	TTTTGTCCAA	12937
GCTTTGGTTG	TCACACAAAT	GGATATATCA	GGAAATATAA	AGGCAGATAA	AACATAACGA	GAACTACTTA	ACATTTGTAG	TAGGACATGA	GGGAATAGA	13037
AAGTGTGTTG	GTTAACATGG	AGGGAGGGAG	AACAGATGCT	TGTAGATGTT	CTTCAACAGA	TATCTTAGGC	ACTGAGACCC	CCTTCGGGAG	CAGAGAGAGC	13137
CCATATCCAC	CACAGTACCT	GACACATAAA	TGCTCAGTAA	TTGTATAATG	AGTCCCATT	TAACTGTTCC	TTAGCCCTGC	TCTATGGAAC	TCTCCCTGTA	13237
ATTCTTGTG	CCATTTTTC	ATTTCTGGAA	TCTTCAGCCT	TTTAGCTGAG	GGCAAAAGAT	TGCTGATTAG	GAAGCAATAT	TTCCCACTCT	CTCGGCAAAA	13337
CAAGCCAAAG	ATCAACAGCA	CAGACCAACAT	ACTGAGCCCT	AAAGGGCAAT	GACAAATGTG	GAGAAATGTA	CAGAGGCTGC	GTATCTTCTT	AGCCAAATGAC	13437
ACAGAATCAC	AATTGAGAAA	ACACAGAGTT	TATTCAATTC	CATTGTGCAT	GCCCTGGACA	AACCAAGCTG	CACCTTTCGT	AACCTATCAC	AATCTCATAT	13537

TGACGGAACA CTTTCTACAG GTAATGTTTG ATTTGGCTGA ACACCTTAGC ATTGCTTCGT AGCAACAAAA TGATAGCTAG TAACAGAAAA AGATCCAGGG 13637
 ATATTACCAC TGTTAGTAGAG GAGAAGAGGCC TTTTAAATTA TTAATTAATT AATTAATAGG ACCAAGTGCC ATCTTTTGGG ATCATGCCCT TAGTGGATTA 13737
 TTGGTAGCAA AGGTTAAAGC TCAAGCTGGT TCCTTTGTCC CCTCGCAAC AGTTGATTGT CCTCCCTTAT CTCCTGAAGT ACCGTAGGCA CTAAGAGCCA 13837
 ATTATTACAT TTGGCTATGC TCAAGATAGT TAAAAGATTT AGATTTCATCA CATATTTCTCC CATATTTCTCC AAAACCAATG AGTCACTCTG 13937
 TTAGCCTGTG TTCCCCCAAG AAAAAAGTCA CAAGCTTATT TTAACCATGT GCAATCCAGG GGGCAAGAGAA AGGAACTGAA GATGAGGCAG AAAGGAAAAAG 14037
 AAAGCAATA AGAGGATGAG TTATCAAACT ACTCGTTTCT TTAACGCAAC TGATTGCTTA ACTTCCTGGG ACTGTCTCCA ATAAGTCAAA TTGGCTCAG 14137
 GTTAGTCCAC CTGAGTGGGA AGAAGCGGTG AAGAATTTTG TCTGTCTAGT TCTGTCTCTC TCTGTCTCTC ATTGGTTAGA AGTTCGACTT ATGGGGAATT AACTCCCTCA 14237
 CATTTCCTAG TTGGTAGACT TGGGTACCAG AGGCATATGG CATCCATGCT CATCGATGAAC AGGGAAGCTT CAAGGCAAAA GACACATAGT GCAGCTATGA 14337
 GCCAAGGCAA TTCAAGGATA CCCCATAGG AGGCTGGTTG ACATCCACCC AGAGCTAATC AGACCATGTC TGGAAAAAGA GACAGGTGAA GCTGGAGAA 14437
 ATGAAGGTGG TGCATAGGAG GTATCTAATA CAGTCACTCA TTTTCAAACT TTCCATGTTA TGATTGCACT GACCAGTGA GATTTCATT GAAAGTTTTA 14537
 CTGTGTCAA ACAGGTACAC AAGGGGAAAG GTGTCTTACA TTGTTTATGT TCGTGTGCTG TCGTGAAGAC AGAAATAGGC TCAAGAGCAG TAACTGTTTT 14637
 TCTTAATTC ACGAGTCTAA GCTAACAGT CCTGAAACAT GGTACTTCCT GTTATTGGTA TTGCATAGGA GAAACAAAGG GAAAGCAGAG AACCTAGAAA 14737
 ATACAAACAA GATGGCAGGA ATAGGCCAAA AATATCAGGA AACACAATTA TTTGTGAATT GGATTAAACT AATCTATTAA TAATGACAACT TTTCAGTTG 14837
 GAGTTAAAAA TTTAATTGTA TACTGTTAAT GAAAGTGATA AATACACTG AATACACTG GAGAGGCCAA ATGAAGGAT ATGAAGGAT AGTCACTG 14937
 AAACTAACA AAAAGAACT AGCAAGCAA TCTTAATATC AGACAAATA GAATCCAGA GAATAATCAT TTCAAAGAC AAGAGATTAT TTTTATTAAT 15037
 AAGGGGAAAT GCATAGGAGA GTAAAGAAAA TGTGGGCCAC TGGAAATGCT AGCACTAATG ACATATTGGT CTTTGGTCTT CATTACCTT ACAGGACCTT 15137
 ATTTCTTCT CTTATGTTTG ATATGTAACC ACCTCAGCCA GCTTCAAGTT GCTTTTGGG CCTAATGGAC TTCTAGCAC TATAATTCTT TTTTTTTAA 15237
 ATGTTTTATT TTAGGTTTAG GGGTACATGT GAAGGTTTGT TACATAGATA AACATGTGCT ACAGGGGTCT GTTGATACATA TTGTACATG ACAGGATAT 15337
 TCAGCTCAGT ACCAAATGAT GATCTTTTCT GCTCCTCTGC CFCATCCCA CTCTCCCTCT CCAGTATCTG TTGTTTCTCT TTTTGTGTTT 15437
 ATAGTTCTT AACACTTAG TCCCGCTTCT AAGTGAGAAC CFCGATGATT TGATTTTGTG TCTTACCTGA GTTTCCTAAG GATGATAGCC TCCAGCTCCA 15537
 TTCAATTTCC CACAAAAGAC TCTTTTCTCT TCTTTTCTAT TCTGTCATAA TTTTCCATGG TATATAGAA CCACATTTTC TTTTCCAGT CTGTCAATGA 15637
 TGGGCATTTA GGTGATTCC ATGTCTGCTA TTCTAACACT GTAATTTCTA AAGACTTCCA TATCTACTT TTATAGGTA TCTGTAAAC AGTCTAGTCA 15737
 TGGAGGCCAA GCAATTTCTA GAATAACTAA GCAATAGAAA TTACACTTCA ATGCAGAAAG CAGTATCTCA CATGAGATTA TGAATTCGCG GTTGCTTTTT 15837
 GTGTTCAAGT AAAAATGTA GTAAAATGAT AACTTTCAGA AAAAATGATT AACACCCAAA CAAGTCTAAC CATATAAATA AATGAGTAA 15937
 GAAAGATTAC TGGATACAGA GTCAACATAC AAATATCAAT TGTATGCTCA TATACACAGA ACATTCAAA AATGATTTT ATAATAGCAT TAAAATTAG 16037
 ACGCTTAGTA ATAAATGTGA AAGGATGTG CAAGAACTCT ACATAAAAA TTATGAGACG TTATTGAGAA AAATTAAGGA AAACCTAAAT AATGAATGA 16137
 ATAGGCAATG TTTATCATT AAGGATACAA TATAGTAAAT ATATCAAAATG TTTACTAATG AATCAATGCG AATACCAAGG TGCCAGCAGG CTTTGTGGT 16237
 GGTGGGAGGT CGGGCAGGAT TCATAGCTA ATTATAAAAT GCATATGGAA ATGCAAAAGG CCAAGGATAG CCAAGACAGT TTTGAGGAGT AATAAATCTG 16337
 TACTATTAC ATACCAGCT GTCAAGACTT ATTATCGAGT TACATTTTAT AAGCAGGTGT GGTATGACA CAAGGATAGA CAAATAGATC AGTGAACAC 16437
 ACTAGAGTGC TCAGAAGCAC ACCTGTACAT ATATAAAGGC TTGATTATG ATAGAGGTGC CAGTGCAGTA GAGAAGGAAA TTATTGGTGT TTTCAATAAA 16537
 AAGTGATAGG TCAATTAGAT ATTCATATGG CATGAAGTAT GAAACAATAA CAATTATAT TCATAGCTTG CAGAAAGCAA AAATTTCTTA AATACAAAA 16637
 AGTGATCACC ATAAAGGAAA AGATTGATA ACTGGACTAT ATTAACAATA AGACTCCTG TCTAGCAAAA GACACTACTT CGACTGAAA GACAACTAC 16737
 AGAGTGAGAC AAGATATCTG CAATACAGAT ACCTAATAAC TGAACCCCAT ACAGTAGTGG TGGGAATTTA AGTTCGTACA ATCATTTAG AAAATTCGTT 16837
 GGCAGTACT CTAGATCTG AACATGTGAT CCGATTAATTA CACTCAATAT TATTAAGCAG TAAAAAGGCA TGTTTATGTC ACCAAAGAT ATATACAGA 16937
 ATGTTTCTTA CACTATTATA CATAAGAGCC AAAAATCTGA AACAAACCAA ATATCCATTA ACAGTAGAAT GAATAAATAA AAGCTGTAAT AGTAATACAG 17037
 TGGAACTACT CACAGCAATG TAAATGAAC ACTGCTGTAT AAAACAACAT GGTTTAATCT CACAGACAAA ATGTTAAATG AAAGACACAG ACGAGTACAT 17137
 ATTGCGAACT TCTGTATTA TTCTAAGAAC TGGCAAGAAC GTGTTACTGT GTTTAGAGTC GTTAGAATG TAACCTATAA AAAGGAAAAA GGGTGAATG 17237
 ATTTGGGAGG GGCATCTTCT GGGGCTTGA TAATGTGCTA TGTATTGGTC AGTTTAGTGT TTAACAGGTC TCATTTACTT TGTGAAACT TACATCAAAA 17337
 TTGTGTGTAT TTTTGAATA TATGTTTATA ATTAATAAAT AGGGTTTTTA AACCTGTAGT TCATAAATTA GTGAAAGTAG AATGTCCTAA CATTAGTTT 17437
 TAAACCAATC AATTATAGTG CTACCATCAT TTTTATGCAT TATTGAGAAG TTTATTTTAC CTTTCTTTCC ACTCTATTT CAAGGCTCCA AAATTTCTCT 17537
 CCCCACGTA TATTGGGGGC AACATGAATG CCCCACATGT ATATTTGACC CATACATGAG TCAGTAGTTC CATGTACTTT TTAGAAATGC ATGTTAAATG 17637

85

Asp Val Thr Cys Asn Ile Lys Asn Gly Arg Cys Glu Gln Phe Cys Lys Asn Ser Ala
 G AT GTA ACA TGT AAC ATT AAG AAT GGC AGA TGC GAG CAG TTT TGT AAA AAT AGT GCT 17724
 127
 Asp Asn Lys Val Val Cys Ser Cys Thr Glu Gly Tyr Arg Leu Ala Glu Asn Gln Lys Ser Cys Glu Pro Ala
 GAT AAC AAG GTG GTT TGC TCC TGT ACT GAG GGA TAT CGA TCT GCA GAA AAC CAG AAG TCC TGT GAA CCA GCA G GTCATAATCT 17807

GAATAAGATT TTTTAAAGAA AATCTGTATC TGAACCTTCA GCATTTTAAAC AAACCTACAT AATTTTAAAT CCTACTTGAA TCTGCTTCTT TTTGAAATCA 17907
 TAGAAAATAT CAGTAGCTTG AATTAGACCA ATTAATTTTC TAGATTGCAT CATATTTTAA ATATAACTAT GTAATCATCT ACAACCTGAA TTCTTTCTGT 18007
 GTCCAAATTTG TCCAAATTTT TTCTCTAACA TTTATATCAT AAAGCAATTA ATTTGTGTGA TTTCTGCATA TGTATTGTGA ATTCATCAAG TCAAAATCAAT 18107
 TAGATAATAT TATATACATA AATAATTTAG TGATAGGCTT CTAGTATAAG GACGGTAAGT TTGAAGCATG ATTTCTATCTG TCGTGGCTAG 18207
 TTTACTCTGA GAAAGTTTAT TTTTATTTGT GGGTCTTAAG CFTGAGTTTAC ACATCTGGTG TCAGAAATGAT TCCGGCAATG AACTGTTTTA TGTTCTGTGA 18307
 GGCATGATCAG CCAATCTAT ACAGGCTGTG GTTTCCAGT CATACCAACC ATGCCACGCT TTTAACAGCT TTTAGTAGTA TTCAGACAT 18407
 CTCCACTCCA TGTTCTGTAT GCTGTTATCT AAAGATGAAA GCAGTAGACA CTTTATTTT TTGAAAAAT TAGGCTCTGC AGGGCTCAAT ATATTGATA 18507
 AATGAGGGGC TTTTGTGAAG CAACTAGAT ATAAATTTCT TTGCAATTTT AAAGCTGTAT ATCTTATTA TTGATGATTA AAATTTGTGA CCAATTTCTCT 18607
 GTAATGTTT GTACTCTGT TACCAGGCAT TACCAGGCAT AAGAAATAAA GAGGAAACCA AGCTTGTGTA GGAGACCTTA ATCTGCGGC 18707
 ACTAGAGGAA TTAAGACAC ACACACAGAA ATATAGAGTA TGGAGTGGGA AACTCAGGGT CTCACAGCT TCAGAGCTGA GAGCCCGGAA CAGAGATTA 18807
 CCCACATAT TATTGACAGC AAGCCAGTCA TAAGATTAT CTTATGTTT CTTATGTTT AATAAGGGA GTTGTCTGCT TAGTTATCTG CAGCAGGAAC 18907
 ATGTCCTTAA GGCACAAATC ACTTATGCAA TTGCTGTGTT TTTAAGAACT CTTTAAAGCA GTTTTCCGCC CTGGGTGGGC CAGGTGTCTC TTGCCCTCAT 19007
 TCTGGTAAAC CCACACCTT CCAGGTGTGA TATCAAGGCC ATCAAGAGCA TATCAAGCAT TTTGTTTATG TTTGTTTATG GCGAGTTTGT GGGCCAGTTT 19107
 ATGGCCAGAT TTGGAGGCT TTGCCAACCA AACCAGAAAG TAGGAATATA TATCTGTCAA ATAAATAGTA GAACTCTTAA GCTTCTGAG GCTGCCCAT 19207
 TGTTCTCTG CTTGTTTCT CACATACACT GTCTCAAGG TAGTCTACCT TGAAGGAGG ATGAATATAT GTGTGGGTGT GTGTCTGTGT ATTTTAACTT 19307
 TAAAAACCTA ACTTCCAGTA TAGACAGATG GCATAGTAC TAAACCTTA CAACTTCTT TATGCTATGA AAGAGAAACA GAATTAGAAA CCACCTCCAA 19407
 CTATTAAGTG TTATATTGTA ATATAGCCTT AGCTTTAGCA TAAATAGTAG GCCAACTTA AATAAGCTT TTTGCTCTT TCTGCTCTT TCAATGATA AGGTCCTT 19507
 TCTGTAGCCA TTGTTGATGT TGTACATTA TACATAAGTA TTTTGAACCT ATTTCTGTT TTTCTCAACA CTTGCTGTCT TCTGATATC TTGTCGACG 19607
 TGTTGTCTAT AGAAATGTCT GTTACAAGGA ATGTGGCTTG AAGGAAAGTG AATTAAGTGA ATGAAATGTG AAGTGACTTT TTGTGACTAC AAATTCGCAT 19707
 TCTGGTAGTC CCCAGTGTAT CAATACATTA TTTTCTTTA GAAATTAAC CAACCAAGG AAAAATGGTG GGCAGGTCTT GGTGAATAT GCTGTGATA 19807
 TTTATTTAG AATCTCTTT GCTAATATTT GAAGCCCAA TAATTTGAAT ACAATGATCT CTCCCCAGAA AATATATAA ATGACCTTGT GAATCTAGAA 19907
 GGCCTTTTAT TCTGCAAAAG AAACCTCTT AATCATAAGC AGCAGAAATC CCATTTACCA AATTTGAAAG TTAAGTTTAC AAAGCATCAA TCATCAGACT 20007
 TCCATTGAG GATGGCAAT GGGAGTAAGA CTTTCTAGTA AAGAAACTAA ACACAAAGT ATTAGACTCT GTAAAAGTCT TACCAATTTT GATTCTGGAA 20107
 CACCTATTCT ATTTCCGTA AGATAGTGAA TTCGGAGCCA AATGTTCTT TCATGAAGGA TTTGAAACT GTCCATGAAA ATACGCAAT CAACTTTTAA 20207
 GCTTGAGACT CTATTCATCTG ATTAGATTTT TTTAAATACT GATGGGCTG CTTCTCAGAA GTGACAAGGA TGGGCTCAA TCTCAATTTT TGTAATACAT 20307

128

GTTCCATTG CCAATGAGAA ATATCAGGTT ACTAATTTT CTCTATTCT TCTAGTG CCA TTT CCA TGT GGA AGA GTT TCT GTT TCA CAA 20397
 Val Pro Phe Pro Cys Gly Arg Val Ser Val Ser Gln

Thr Ser Lys Leu Thr Arg Ala Glu Ala Val Phe Pro Asp Val Asp Tyr Val Asn Ser Thr Glu Ala Glu Thr Ile Leu Asp
 ACT TCT AAG CTC ACC CGT GCT GAG GCT GTT TTT CCT GAT GTG GAC TAT GTA AAT TCT ACT GAA GCT GAA ACC ATT TTG GAT 20478

Asn Ile Thr Gln Ser Thr Gln Ser Phe Asn Asp Phe Thr Arg Val Val Gly Gly Glu Asp Ala Lys Pro Gly Gln Phe Pro
 AAC ATC ACT CAA AGC ACC CAA TCA TTT AAT GAC TTC ACT CGG GTT GTT GGT GGA GAA GAT GCC AAA CCA GGT CAA TTC CTT 20559

Trp Gln
 TGG CAG GT ACTTTTACT GATGGTGTG CAAAACCTGGA GCTCAGCTGG CAAGACACAG GCCAGGTGGG AGACTGAGGC TATTTTACTA GACAGACCTA 20657

TTGGGATGTG AGAAGTATTT AGGCAAGTTT CAGCACTAAC CAATGTGAGA AGGCCTCCAG AGATGAGCAG TTGGTGAAG AGAGGCTCAA AACAGCTAC 20757
 CATACAGGTC AAGAAGAAAT TTGGCATTAAG GAAACAGCAT AGCAGGATTC CAGACAGGCA ACTGGTCAAC AACATGAAG TCTGGAAGAA AGGTGCGCAT 20857
 ACTCAGGTTA AGGCGACTAC TTCAGCTTCA GCCCTTGCAA AAATCTGGTA GAGTGTGAA GTCTTTAGG TAAGAAAAAT TGGATTATTT AAAAGGGTGA 20957
 AAGAAAGGGA CTCAGAGGAG AAGGATTAAG GCAAGAACTA GGTTCACAGA AACAGGCGAT GAGAGAGAGT CTTGATCTAC CACTATAGTT CTCGTGGTAG 21057
 CATCAGAAAT ACCTGGGAAC TGAAGAAATG AAATTTCTGCT GCTCTACACT AGACCTACCA AATCAGATA TCTAGGGGGT GGGGCGGAC AGTCTGTGCG 21157
 CAAACAGCA CTCGAGGTGA TTTTGTGCA CATTATAGT GTGAAACTAG GCGAGGTGCA GTGGCTCATG CCAATAATCC CAGCAGCTTG GAGTCTGAG 21257

ACGGAGGAT TGCTTAAACC CAGGAGTTTG AGACCAGCCT GGGCAACAG GCGAAACCC ACCTCTAATT AAAAAAATA CAAAATTTAG CTAGGTGTGA 21357
 TGGCTCCCAC CTGTGCTCC AGCTATTAC GAGGCTGAGG TGGGAGAATC ACCTGAGCCT GGAAGTCTGA GGCTGAGTG AATTGTGATC ACACCAGTGC 21457

GTCTAATAAA	ATTGTTGTTG	AATAAATTGG	GCTAAAGGCA	GAAGGGTCAT	AATTTTCAGAA	CCCACGTCGC	ACCGTCCTCC	AAGCATCCAT	AGTTCTTTTG	30329
ATATACCCCT	ATTATCACTC	ATTTTCAGTGA	GGTACAATTA	GTTCTTTGAT	TAGCCATTTT	CATACCAGGA	GGCCTTCCCA	AAAATCAGTG	TCATGTCAAC	30429
GATCCTTTTA	TCTCTGGTGC	TGGGCACAAC	CTGTAGCAGG	TCCTCAGAAA	ACAAACATTT	GAATTAATGG	CCCATGAGT	TGTGTCTCAA	AAAAGGGGTG	30529
AGGATACTTG	AAATTTGGAA	AATCTAGGAT	AATTCATGAC	TAGTGGATTG	ATTATCACCA	ATGAAAGGCT	TATAACAGCA	TGAGTGAACA	GAACCATCTC	30629
TATGATAGTC	CTGAATGGCT	TTTTGGTCTG	AAAAATATGC	ATTGGCTCTC	ATTACATTTA	ACCAAAATTA	TCACAATATA	AGAATGAGAT	CTTTAACATT	30729
GCCAATTAGG	TCAGTGGTCC	CAAGTAGTCA	CTTAGAAAA	CTGTGTATGT	GAAATACTGT	TTGTGACTTA	AAATGAAATT	TATTTTTAAT	AG ²³⁴ Glu ↑ GT GAA	30826
His Asn Ile	Glu Glu Thr	Glu His Thr	Glu Gln	Lys Arg Asn	Val Ile Arg	Ile Ile Pro	His His	Asn Tyr Asn	Ala Ala	
CAT AAT ATT	GAG GAG ACA	GAA CAT ACA	GAG CAA	AAG CGA AAT	GTG ATT CGA	ATT ATT CCT	CAC CAC	AAC TAC AAT	GCA GCT	30907
Ile Asn Lys	Tyr Asn His	Asp Ile Ala	Leu Leu	Glu Leu Asp	Glu Pro Leu	Val Leu	Asn Ser Tyr	Val Thr Pro	Ile Cys	
ATT AAT AAG	TAC AAC CAT	GAC ATT GCC	CTT CTG	GAA CTG GAC	GAA CCC TTA	GTG CTA	AAC AGC TAC	GTT ACA CCT	ATT TGC	30988
Ile Ala Asp	Lys Glu Tyr	Thr Asn Ile	Phe Leu	Lys Phe Gly	Ser Gly Tyr	Val Ser Gly	Trp Gly	Arg Val Phe	His Lys	
ATT GCT GAC	AAG GAA TAC	ACG AAC ATC	TTC CTC	AAA TTT GGA	TCT GGC TAT	GTA AGT GGC	TGG GGA	AGA GTC TTC	CAC AAA	31069
Gly Arg Ser	Ala Leu Val	Leu Gln Tyr	Leu Arg	Val Pro Leu	Val Asp Arg	Ala Thr Cys	Leu Arg	Ser Thr Lys	Phe Thr	
GGG AGA TCA	GCT TTA GTT	CTT CAG TAC	CTT AGA	GTT CCA CTT	GTT GAC CGA	GCC ACA TGT	CTT CGA	TCT ACA AAG	TTC ACC	31150
Ile Tyr Asn	Asn Met Phe	Cys Ala Gly	Phe His	Glu Gly Gly	Arg Asp Ser	Cys Gln Gly	Asp Ser	Gly Gly Pro	His Val	
ATC TAT AAC	AAC ATG TTC	TGT GCT GGC	TTC CAT	GAA GGA GGT	AGA GAT TCA	TGT CAA GGA	GAT AGT	GGG GGA CCC	CAT GTT	31231
Thr Glu Val	Glu Gly Thr	Ser Phe Leu	Thr Gly	Ile Ile Ser	Trp Gly Glu	Glu Cys Ala	Met Lys	Gly Lys Tyr	Gly Ile	
ACT GAA GTG	GAA GGG ACC	AGT TTC TTA	ACT GGA	ATT ATT AGC	TGG GGT GAA	GAG TGT GCA	ATG AAA	GGC AAA TAT	GGA ATA	31312
Tyr Thr Lys	Val Ser Arg	Tyr Val Asn	Trp Ile	Lys Glu Lys	Thr Lys Leu	Thr STOP				
TAT ACC AAG	GTA TCC	CGG TAT	GTC AAT	TGG ATT	Lys Glu GAA	AAC TGA	ACT TAA	TGAAAGATGG	ATTTCCAAGG	31399
GGAATTGAAA	ATTAACAGGG	CCTCTCACTA	ACTAATCACT	TTCCCATCTT	TTGTTAGATT	TGAATATATA	CATTCTATGA	TCATTGCTTT	TTCTCTTTAC	31499
AGGGGAGAA	TTCATATTTT	ACCTGAGCAA	ATTGATTAGA	AAATGGAACC	ACTAGAGGAA	TATAATGTGT	TAGGAAATTA	CAGTCATTTC	TAAGGGCCCA	31599
GCCCTTGACA	AAATGTGTGA	GTTAAATCTC	CCACTCTGTC	CATCAGATAC	TATGGTTCTC	CACATATGGCA	ACTAATCTAC	TCAATTTTCC	CTCCTTAGCA	31699
GCATTCATC	TCCCGATCT	TCTTTGCTTC	TCCAACCAAA	ACATCAATGT	TTATTAGTTC	TGTATACAGT	ACAGAGTCTT	TGGTCTACTC	TATCACAAGG	31799
CCAGTACCAC	ACTCATGAAG	AAAGAACACA	GGAGTAGCTG	AGAGGCTAAA	ACTCATCAAA	AAACACTACTC	CTTTTCTCTT	ACCTATCTCC	TCAATCTTTT	31899
ACCTTTTCCA	AATCCCAATC	CCCAATCAG	TTTTTCTCTT	TCTTACTCCC	TCTCTCCTCT	TTACCCTCCA	TGGTCGTAA	AGGAGAGATG	GGGAGCATCA	31999
TTCTGTTATA	CTTCTGTACA	CAGTTATACA	TGCTATCA	ACCCAGACTT	GCTTCCATAG	TGGAGACTTG	CTTTTCAGAA	CATAGGGATG	AAGTAAGGTG	32099
CCTGAAAAGT	TTGGGGGAAA	AGTTTCTTTT	AGAGAGTTAA	GTATTTTAT	ATATATAATA	TATATATAAA	ATATATAATA	TACATAATAA	ATATATAGTG	32199
TGTGTGTGTA	TGCGTGTGTG	TAGACACACA	CGCATACACA	CATATAATGG	AAAGCAATAAG	CCATTCTAAG	AGCTTGTATG	GTTATGGAGG	TCTGACTAGG	32299
CATGATTTCA	GGAAGGCAAG	ATTGGCATAT	CATTGTAAC	AAAAAAGCTG	ACATTGACCC	AGACATATTT	TACTCTTTCT	AAAAATAATA	ATAATAATGC	32399
TAACAGAAAG	AAGAGAACCG	TTCGTTTGCA	ATCTACAGCT	ATGAGAGACT	TTGAGGAAGA	ATTCACACAGT	GTGCTTTCAG	AGCCAAAGCA	32499	
GAAGTTGAAG	TTGCCTAGAC	CAGAGGACAT	AAGTATCATG	TCTCCTTTAA	CTAGCATACC	CCGAAGTGA	GAAGGGTGCA	GCAGGCTCAA	AGGCATAAGT	32599
CATTCCAATC	AGCCAACATA	GTTGCTCTTT	TCTGTTTTCG	TGTTTCAACAT	GGAACATTTT	GATTATAGTT	AATCCTTCTA	TCTTGAATCT	TCTAGAGAGT	32699
TGCTGACCAA	CTGACGTATG	TTCCCTTTG	TGAATTAATA	AATCTGGTGT	CTGGTTCATA	CATTGGCTTT	TTGTGGATTG	CATTGATGTG	AATCAGTAC	32799
CCTGTATTTG	ATGATGCATG	GGACTCATCTA	CAAAATCACT	CTGACCTGTC	CAAGCTGCTG	CCTTCTCTCTG	CCCCAACCTC	ACCCGCCGCC	AGGCTCACT	32899
CTTGCTAGTT	CCTTTAGTTC	TTTTAGTCAA	TATATTTTGT	TCTTCGATA	TAAGTATAAA	TAAACATATT	TTTAAATTTT	TTGGCTGGGC	CCAGTGGCTC	32999
ACGCCATATA	TCCAGCACT	TCTGGAGGCC	AAGGTGGGCG	GATCACCTGA	GGTTAGGAGT	TTCAGGCCAG	CCTGGCCAAC	ATGGTGAAAC	CCTGTCTCTA	33099
CTAAAAATAG	AACAATTAGC	TGGGCTTGGT	AATGTGCACC	TATAATCCCA	GCTACTGGGG	AGGCTGAGGC	AGGAGAATCA	CTTGAGCCTG	GGGAGCAGGG	33199
GTGTGGGAG	GTTGCGATGA	GACAAGATCG	CACCAGTGCA	CTCCCATCTC	TGGGTGACAG	AGTGAGACTC	TGTTCTCAAAG	AAAATAAATA	AATAAATACA	33299
TTTCTTGAGG	CGTTTCTTGT	TAAATCATTC	ATGGAGAGGC	ATCCCAACA	CCACATTCAA	CAAAACACTC	TGAAAAATGT	TTTCAAATGC	AATATAACAC	33399
AGCAGAGATT	TGATGCTCTG	TTATCCAGTT	TTCATATAAG	GCTGTGTGAG	CTGTGTCCCA	GAGAGGACAG	TGGTCTGAAT	CCACTTGAGA	CAGAAATGGG	33499
TCTAATCAAC	TGTGAGTATG	GCCTTCAATA	AGTCACCTCT	CATTTGGGAA	TTTGATTTCT	CCACTTGTAT	AATGAGAGTA	TTTGACAGGA	TGCTCTCCCA	33599
AATCCCTTGC	AAATTTGTGA	GTCGTGTGAT	TCATGTTTTT	ATTTTATTC	CTTCATCCAA	CAATATGTC	AGGAGTAAT	GCTGTGTGCC	AAATACCAAC	33699
AGTATTCATT	AAATGTGAAT	TCAGATTTTA	TATATATATA	AATAATGTAT	AAATGTGAT	AAATGCTTTG	TGAGTGCTTA	CTACACTGCT	AGACATAGT	33799
TGCTCAATAA	CTTGTAGCT	GAATCAGAA	CCATGTTTAT	CCAGAGTAG	CAATTAGTCT	TGCATCGAGT	ATCGTGAAAG	AAGGCCACAC	TTAAATAAGA	33899
ATAATGCCFG	GGGTTTAGGT	TTTATGAAAA	AATGAAAGGA	AATTAGTTCT	GCTTTTGTG	ACTAAAGGAA	GGGAAGAGAG	AAGAGACACT	ATAATGTGCT	33999
GCCTCAGATT	TAAGGAGGAG	GCTAATTCAT	GCATTAACAA	CGTTACTTCA	AAATTTGAAT	ACCAAAGGTC	TGTAGCCTCA	GCACCTTCAA	ATTGGTAAAA	34099
GTAAGACACT	CTGGCCTTGT	TTCCATAGAG	ACCACCCCTT	ACAAAGGCAC	CAATGGGAAA	CTGGCCTCAG	GACTCCTGTT	ATTGGTCTTC	TCTGTGGGAG	34199
AGAAAGGAGC	TCTTGGACCC	ATAAATCTCT	GAGCCACAGT	TCCTTTTGGC	ATGGGCTCAA	AAATGATTGA	ATTCATCATG	AGCCACCTGT	GGCATATTGC	34299
CACACTAAAC	ATGTGGGGCC	TTTAAAGTCA	CTAAGAGCCA	ATGTCTTCAG	AGCCAGCCCT	GGCTTGATTC	TACCTAGGGC	ATTTCAGATT	GCCATATAAG	34399
AATCATTAGT	GCCTTCAAAA	TTACTGTAGA	TACTTTGCCT	AAATAGACTA	AAACATGCTG	CCGTCATATT	GGAAGTGACA	GATTAAAAAT	GAATCTGTGC	34499
CAAGTGAAGG	AAAGTGTGCT	AATATAATGC	AGTCATTTTA	ACTTGTGCTT	TAAGTGTGAT	TGTTTGTAGT	TCTTTTGAAT	ATTATTTGTT	TATACTAGC	34599
AGGAACGAAG	TACTGTCCAA	TTTTCTCTGC	CAAGGAAAAA	AGAAAAGGTG	TTCTTCTCTA	CTTACCTGAA	CCAAACAGCA	CCAGTTTACA	AAATGGCCTA	34699
ATTATAATTG	CTAAACAAGT	TCCGAATGCT	TACAGTCTAA	TCCAAGAATG	TCAGAGCTGC	AAAGGCCCTT	AAACACCATC	CAATCCACTC	CACATCTTTA	34799
GCAGATGAAG	AGATTGAGGG	CAACATAAGG	CCAGGCCCAA	GATAACACAA	TGACAGCCAG	GACTAGAGCT	CAAGTCTCCC	ACCTGCACT	TTGAAAGAAT	34899
AATGCTTTCA	ACTGGAGTAC	ATTAACCTTA	CTGTCTATAT	TTTTTAGGGCA	GCTGGGGCACT	TCTGCTATGG	TGGCAATCTC	CTCAACAACC	CTGGGACTGA	34999
AAACTGCCCT	GAATCTTACT	TAACAAATCT	CTAATTGACC	AAAAGGTGAC	GAAATCAAGG	AGACCAATTA	GGTAGCCCTT	GAAAGCAAGA	GTGGC	35094

FIGURE 3: Nucleotide sequence for the gene for human factor IX. The proposed initiation transcription site (nucleotide 1) and the poly(A) addition site (nucleotide 32757) are identified by solid circles. The solid vertical arrows indicate the intron-exon splice junction. The five Alu repetitive sequences have been underlined, while the 50-base insert in intron A and the AATAAA sequence in exon VIII are boxed. The apparent cleavage or termination site at the 3' end of the gene (CATTG) was underlined with a dashed line.

acetic acid containing 10% methanol for about 20 min before drying. The DNA sequence was then read at least twice to eliminate reading errors, and the data were analyzed by the programs of Staden (1977, 1978) with a VAX computer, as well as by DNA/protein sequence analysis programs (International Biotechnologies, Inc.) written by Pustell & Kafatos (1982a,b, 1984) using an IBM PC/XT. An extensive homology search analysis against other mammalian gene sequences as well as protein sequences was also performed with the DNA and protein analysis programs of Intelligenetics with the kind help of Dr. Mike Parker at Zymogenetics, Seattle, WA.

RESULTS

Approximately 9×10^6 bacteriophage from the λ Charon 4A library were screened by the plaque hybridization technique

for the gene coding for human factor IX. Positive phage were plaque purified, and their DNA was isolated and subjected to *EcoRI* restriction enzyme digestion and Southern blotting (Southern, 1975). The *EcoRI* restriction map led to the identification of four overlapping phage (FIX λ 36, FIX λ 61, FIX λ 53, FIX λ 6) with human genomic DNA inserts ranging from 10 to 15 kilobases (Figure 1). The DNA inserts from the *EcoRI* digests were then subcloned into the *EcoRI* site of pBR322 and prepared for the sequencing strategy shown in Figure 2. These four phage were then shown by DNA sequencing to contain the coding region for factor IX starting with valine at position -17 in the prepro leader sequence and extending to the carboxyl-terminal threonine.

These four phage, however, did not contain the 5' end of the gene including amino acid residues -46 to -17 in the prepro

Table I: Location and Size of the Exons and Introns in the Gene for Human Factor IX

exon	nucleotide positions ^a	nucleotide length ^a	amino acids ^b	intron	nucleotide positions	nucleotide length
I	1-117	117	-46 to -17	A	118-6325	6206 ^c
II	6326-6489	164	-17 to 37	B	6490-6677	188
III	6678-6702	25	38-47	C	6703-10391	3689
IV	10392-10505	114	47-85	D	10506-17668	7163
V	17669-17797	129	85-128	E	17798-20362	2565
VI	20363-20565	203	128-195	F	20566-30038	9473
VII	30039-30153	115	196-234	G	30154-30821	668
VIII	30822-32757	1935	234-415			

^a Includes 30 nucleotides at the 5' end and 1390 nucleotides at the 3' end that are not translated. ^b Amino acids coded for by each exon; negative numbers refer to amino acids in the prepro leader sequence. ^c Includes the 50 extra nucleotides in the clone from FIX λ 4243.

leader sequence. In order to isolate the 5' end of the gene, a second genomic library was prepared from human 5X fibroblast cells, and approximately 5×10^5 phages were again screened by the plaque hybridization technique employing a 5' cDNA fragment or a genomic fragment as a probe, as described under Experimental Procedures. One of the positive phages (FIX λ 4243) that was plaque purified from this library was found to hybridize with both probes, indicating that it contained the 5' end of the gene and overlapped the genomic inserts in FIX λ 61 (Figure 1). The DNA from the insert of this phage was also subcloned into pBR322 and prepared for DNA sequencing.

The entire nucleotide sequence for the gene coding for human factor IX is shown in Figure 3.¹ A major portion of the coding and intron-exon junctions were sequenced by both the chemical degradation method and the dideoxy chain termination method, while the remainder of the gene was sequenced by the dideoxy chain termination method. Approximately 85% of the total gene was sequenced 2 or more times, and about 35% of the sequence analysis was performed on both strands. The nucleotide numbering was designated by assigning the proposed transcription initiation site (Anson et al., 1984) as nucleotide number 1.

The gene for factor IX contains eight exons and seven introns. The possibility of an additional intron(s) in the 5' noncoding region cannot be ruled out, however, since the largest cDNA employed in these experiments (Kurachi & Davie, 1982) started at nucleotide number 30 and would not identify an additional intron(s) in the 5' end of the gene. The location of each exon and intron and their sizes are shown in Table I. Intron F was the largest intron and contained 9473 nucleotides. Introns B and G were the smallest and contained 188 and 668 nucleotides, respectively. The eight exons also varied considerably in size. For instance, exon III coded for only eight amino acids, while exon VIII coded for 182 amino acids. The introns in the gene for factor IX made up about 95% of the total DNA present in the gene.

The coding sequence in the eight exons in the gene for factor IX agrees well with that previously reported for the cDNA (Kurachi & Davie, 1982; Davie et al., 1983; Jaye et al., 1983; Anson et al., 1984; Jagadeeswaran et al., 1984). These exons code for 415 amino acids that are present in the mature protein circulating in plasma. The first two exons also code for a prepro leader sequence that is removed during the biosynthesis and processing of a single-chain polypeptide. This prepro leader sequence contains three potential Met residues for the initiation of translation. The first Met occurs at position -46, while the remaining two Met residues are located at -41 and -39. The Met at position -39 could be the principal initiation site for factor IX biosynthesis since it shows the strongest

homology with the consensus sequence (A/G)CCAUGG. This sequence is preferred by more than 250 cellular and viral mRNAs (Kozak, 1984). Further experiments are necessary to clarify the precise site of polypeptide initiation.

There are several potential TATA sequences (Goldberg, 1979) upstream from the prepro leader sequence in the gene for factor IX. On the basis of S1 nuclease mapping, Anson et al. (1984) suggested the initiation site as the A-numbered nucleotide 1 (Figure 3) and the TATA box as the TGTA sequence located 21 nucleotides upstream from this proposed initiation site starting with nucleotide number -27. Two additional potential TATA sequences are also present that are further upstream in the gene for factor IX. The first (GAT-GAA) starting with nucleotide -265 is present in the sequence of TCCCACTGATGAA. This sequence of 13 nucleotides show considerable homology (12 of 13 nucleotides) with that recently proposed as containing the TATA box for human factor VIII (Gitschier et al., 1984). The next potential TATA box starts at nucleotide -411 and has a sequence of TATA-TAA. Whether or not the latter two sites are associated with polymerase binding and mRNA initiation is not known at the present time. These three potential TATA consensus sequences all lack a nearby CCAAT regulator sequence (Efstratiadis et al., 1980; Benoist et al., 1980).

The gene for factor IX, as well as that for factor VIII (Gitschier et al., 1984), lacks a GC-rich region in the 5' end. With two other genes located on the X chromosome (hypoxanthine phosphoribosyl transferase and glucose-6-phosphate dehydrogenase), the GC-rich region has been proposed as a region for methylation that may be involved in the mechanism leading to the X inactivation of these genes on one of the chromosomes in females (Yen et al., 1984; Melton et al., 1984; Wolf et al., 1984a,b; Toniolo et al., 1984).

The poly(A) addition starts at an A (nucleotide 32757, Figure 3), which is 16 nucleotides downstream from the consensus sequence of AATAAA (Anson et al., 1984). This A, where polyadenylation occurs, is 23 nucleotides upstream from the sequence of CATTG. This latter sequence corresponds to the consensus sequence of CA(T/C)TG and may also be involved in the polyadenylation or cleavage at the 3' end of mRNA (Berget, 1984).

The sequences at the 5' and 3' splice junctions and the splice junction types (Sharp, 1981) for the gene for factor IX are shown in Table II. These various intron-exon splice junctions are very similar to the consensus sequences summarized by Mount (1982) and follow the GT-AG rule of Breathnach & Chambon (1981). Also, the seven introns occurred either between amino acids (introns B and F, type 0) or between the first nucleotide in the triplet coding for a given amino acid (introns A, C, D, E, and G, type I). A search for the consensus sequence of CTGAC within 100 nucleotides upstream to the 3' intron boundary of the seven introns was negative. This sequence is a potential internal signal sequence for splicing

¹ This DNA sequence for the gene for factor IX has been deposited in the NIH GenBank where it is available to scientists.

Table II: Intron-Exon Splice Junction Sequences in the Gene for Human Factor IX

intron	splice junction sequences			splice junction type ^a
	exon 5'	intron	3' exon	
A	CAG	GTTTGT.....TTTCAG	T	I
B	ACA	GTGAGT.....TTATAG	A	O
C	TTG	GTAAGC.....TCAAAG	A	I
D	TAG	GTAAGT.....TTTTCAG	A	I
E	CAG	GTCATA.....TTCTAG	T	I
F	CAG	GTACTT.....TCACAG	G	O
G	CAG	GTAAT.....TAATAG	G	I
consensus sequence ^b	CAG	GT ^A AGT.....TT ^T CC ^N AG	G	

^aFrom Sharp (1981). ^bFrom Mount (1982).

of the introns in the gene for globin (Keller & Noon, 1984). The sequence of CTAAT, which may be an internal signal in the first intron of the ϵ globin gene, was observed in intron D but not in the other six introns of the gene for factor IX.

A difference in the sequence of the overlapping clone from FIX λ 4243 with that of clones from FIX λ 36 and FIX λ 61 was also noticed. This difference was due to an extra 50 base pairs (nucleotides 5505–5554) present in FIX4243 and absent from the 5' end of the FIX λ 36 and FIX λ 61 clones (Figure 1). This 50-base insert has also been reported recently by Winship et al. (1984), who showed that it is due to a polymorphism in the gene for factor IX. The presence of this insert of 50 nucleotides reduces the size of the *Hinf*I fragments in this region from 699 (nucleotides 4958–5656) to 649 nucleotides. Also, the *Dde*I fragments are reduced in size from 1739 (nucleotides 5070–6808) to 1689 nucleotides.

A second polymorphic site in the gene for factor IX is a *Taq*I site (Camerino et al., 1983; Giannelli et al., 1984) that

starts at nucleotide 11 111 following exon IV. The presence or absence of this polymorphic site gives rise to *Taq*I fragments of 1380 (nucleotides 9732–11 111) and 463 (nucleotides 11 112–11 574) nucleotides or 1843 nucleotides (nucleotides 9732–11 574), respectively.

A third polymorphic site has been reported in exon VI at nucleotide number 20 422 (McGraw et al., 1984). This is due to a change of a G to an A resulting in the substitution of Ala-3 (GCT) in the activation peptide by Thr (ACT). A fourth polymorphic site is present in intron C (nucleotide number 7076) in which a G has been changed to a C (Winship et al., 1984). This results in the loss of the *Xmn*I recognition sequence of GAAGCCCTTC. The presence or absence of this polymorphic site gives rise to large *Xmn*I fragments of 5119 (nucleotides 1962–7080) and 6467 (nucleotides 7081–13 547) or 11 586 nucleotides (nucleotides 1962–13 547), respectively. These various polymorphic sites have been very useful for establishing methods for carrier detection for factor IX deficiency (Camerino et al., 1983; Winship et al., 1984; Giannelli et al., 1984; Peake et al., 1984).

Four highly repetitive Alu sequences (Deininger et al., 1981) are present in the gene for factor IX (Figures 4). The first Alu sequence was located in intron A (nucleotides 4333–4628), and the next three were found in intron F (nucleotides 21 207–21 510, 22 898–23 126, and 28 572–28 844) (Figures 2 and 3). A fifth Alu sequence was identified in the flanking region of the 3' end of the gene (nucleotides 32 983–33 297) in a position analogous to an Alu sequence in the 3' end of the gene for human factor VIII (Gitschire et al., 1984). Alu repeat number 3 was about 70 base pairs shorter than the other four Alu repeats and started 14 nucleotides prior to the first of the two highly conserved repeating sequences of CCAGCCTGG. Each Alu sequence was approximately 87% identical with the consensus sequence of Schmid & Jelinek (1982). The five Alu repetitive sequences contain short flanking repeats on each end, some of which were not immediately flanking the Alu sequences (Figure 5). These

CONSENSUS SEQ.	GGCTGGGCGT	GGTGGCTCAC	ACCTGTAATC	CCAGCAGCTT	GGGAGGCCGA	GGTGGGTGGA	TCACCTGAGG	TCAGGAGTTC	AAGACCAGCC	TGGCCCAACAT
REPEAT #1	...CT...A...	A.....	CA.....C...	..CA..CA..	T....	G.C.....	J..			
REPEAT #2	...CA..T..C	A.....T	G..AA.....	...xxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xxxxxxx	xxx.....T	G.....	...G....C
REPEAT #3	...C...T..C	A..C..x...	G.....	A...	..C...C...	xx...	..GA...A...	G.....T...		
REPEAT #4	CC	A.....	G...A.....	C	T.....A...	C...	T.....T	C..G.....		
CONSENSUS SEQ.	GGTGAAACCC	CGTCTCTACT	AAAAATACAA	AAATTAGCCG	GGCGTGGTGG	CGCGCGCCTG	TAATCCAGC	TACTCGGAG	GCTGAGGCAG	GACAATCGCT
REPEAT #1	G..T....	T...	A...	T...	G..T....	T...	T...	A...		
REPEAT #2	A.....A...	TAAAT	TA	..T...A...	..T..C.A...	..GC.....	..T..A...	TG.	A.C	
REPEAT #3	A.....T..C	A	C	AG.....A	..G.....	..A.....	G..G			
REPEAT #4	A.....	A..T...	A...	..A.....	..AT.....	..G....xxx	xxxxxxxxxx	xxxxxxxxxx	T...	
REPEAT #5	T.....	G..C.....	T...	..T...AA	T..T..A..A	G.....	G.....	A...		
CONSENSUS SEQ.	TGAACCCAGG	AGGTGGAGGT	TGCAGTGAGC	CGAGATCGCG	CCACTGCACT	CCAGCCTGGG	CAACAGAGCG	AGACTCCATC	TCAAAAAAAA	AAAAAAAAAA
REPEAT #1	TG..	..A.....	T.....A		G.....A	G.....	xx.....			
REPEAT #2	...G..TG..A	..A..C...C	AT	T..T...A..A	T.....A	TG.....TA	CTT...	C..G	G...	
REPEAT #3	GG..	..C...C..C	G.....	C...		G.....	G.....	G..G		
REPEAT #4	TG..	..C...C..C	A...T..A	T...	x	TG...G..A	G.....	xx.....	G..G	
REPEAT #5	TGGGGAG	GTGC	A	..A.....A	...G.....T	TG.....T	TG..	G.....	T...T...T	

FIGURE 4: DNA sequence for the four Alu sequences within the gene for human factor IX and the Alu sequence flanking the 3' end of the gene. Dots represent identity with the consensus sequence of Schmid & Jelinek (1982), while an x represents a deletion. The two highly conserved sequences of CCAGCCTGG have been underlined in the consensus sequence.




FIGURE 5: Direct flanking repeats in the Alu sequences in the gene for human factor IX. The orientation of each flanking repeat relative to the Alu sequence is indicated by the arrows.

sequences are not conserved from one Alu sequence to the next and range in size from 7–14 base pairs.

Other repetitive sequences were also observed in intron D and the 5' flanking region of the gene for factor IX. These include *KpnI* repetitive elements (Lerman et al., 1983; Di-Giovanni et al., 1983; Potter, 1984) and a 1.9-kb *HindIII* repetitive sequence (Manuelidis, 1982). The first *KpnI* repeat containing about 2600 nucleotides extends approximately from the beginning of the nucleotide sequence shown in Figure 3 (–2965 to about –370). Within this *KpnI* region, two unique internal repeat sequences consisting of about 60 bp (nucleotides –2490 to –2424 and nucleotides –982 to –921) and about 80 bp (nucleotides –1956 to –1881 and nucleotides –445 to –364) were also observed. Part of a second *KpnI* repeat was identified in the most distal portion of the gene as shown in the map in Figure 2 (sequence data not shown). This *KpnI* repeat extended from the first *EcoRI*-1 site to approximately 1600 bases downstream and terminated near the first *HindIII* restriction site (Figure 2). This *KpnI* repeat was followed by a 1.9-kb *HindIII* repeat (nucleotides between the first and second *HindIII* sites, Figure 2) that showed considerable homology to that reported by Manuelidis (1982). The *HindIII* repeat apparently is a subfamily of the *KpnI* repetitive DNA (Singer, 1982). The third *KpnI* repeat was about 2 kb in length (nucleotides 15 200–17 300 within intron D), and its sequence showed only weak homology to that previously published (Manuelidis, 1982). Its exact boundaries were difficult to define.

The base composition of the gene for factor IX was calculated as 32.4% A, 28.6% T, 19.6% G, and 19.4% C. The dinucleotide frequency (Table III) was in reasonable agreement with that predicted from a random distribution of all four bases except for CG, which was 0.79% with a predicted value of 3.9%, and TA, which was 7.3% with a predicted value of 9.2%. The low frequency of the dinucleotides CG accounts for the relatively low number of *SmaI* (1), *HhaI* (11), and *HpaII* (22) restriction sites in the gene. The various dinucleotide frequencies are similar to those summarized by Nussinov (1981) for a large number of eukaryotic genes.

The gene for factor IX contains alternating purine–pyrimidine sequences present in intron A (nucleotides 4981–5605) and the 3' noncoding region of the gene (nucleotides 32 148–32 245) (Figure 6). These sequences provide regions for potential hairpin loops in the mRNA for factor IX prior to the removal of intervening sequences. These purine–pyrimidine sequences may also form left-handed helical structures or the Z form of DNA in the gene (Rich et al., 1984). These structures have been identified by cytological techniques in the polytene chromosomes of *Drosophila* salivary glands (Nordheim et al., 1982).

An intensive homology search employing the computer programs of Intelligenetics was also carried out by comparing the gene for factor IX with the DNA sequence filed in the NIH genetic sequence data bank (Genbank Release 26.0, updated November 7, 1984). In addition to the Alu and *KpnI* repetitive sequences, more than 70 other short interdispersed sequences (10–13 nucleotides in length) that appear 2 or more times and contain 11 or more perfectly matched sequences were observed within the gene. In addition, a large number of unique stretches of 15–20 nucleotides or more were found in the gene for factor IX as well as in the genes for other proteins, including different serine proteases, immunoglobulins, globulin, interferon, fibrinogen, fibronectin, collagen, histones, enkephalin, interleukin 2, and oncogenes (K-ras and C-myc). These homologous sequences were distributed throughout the gene for factor IX, and some sequences were found to be common to three or more genes. For instance, the sequence GGGCTGACTCCCTCACCTCCTC (starting at nucleotide number 7266) in the gene for factor IX was highly homologous with sequences present in the genes for human prothrombin, complement B, and class II histocompatibility antigen. Short regions in exon II (nucleotides 6421–6443) were also found to be highly homologous to a sequence in bovine adrenocorticotropin, while another sequence (nucleotide 10 451–

Table III: Frequency of Dinucleotides in the Gene for Human Factor IX

dinucleotide	number obsd	frequency predicted (%) ^a	frequency obsd (%)	ratio of predicted/observed	
				factor IX	other genes ^b
AA	4274	10.4	11.1	1.07	1.13
AC	2111	6.3	5.5	0.87	0.90
AG	2775	6.3	7.3	1.16	1.15
AT	2165	9.2	8.2	0.89	0.83
CA	2906	6.3	7.6	1.21	1.16
CC	1758	3.8	4.7	1.24	1.17
CG	281	3.9	0.7	0.18	0.37
CT	2448	5.6	6.4	1.42	1.24
GA	2359	6.3	6.1	0.97	0.97
GC	1455	3.8	3.9	1.03	1.05
GG	1787	3.9	4.8	1.23	1.16
GT	1781	5.6	4.9	0.88	0.86
TA	2786	9.2	7.3	0.79	0.73
TC	2071	5.6	5.5	0.98	0.94
TG	2598	5.6	6.9	1.23	1.30
TT	3445	8.2	9.1	1.11	1.06

^a Predicted from random distribution. ^b Data from Nussinov (1981) on the basis of eukaryotic genes equivalent to 4.3×10^4 nucleotides.




FIGURE 6: Two different alternating purine-pyridine sequences in the gene for factor IX. The two potential hairpin sequences are from intron A (starting at nucleotide 4981) and the 3' noncoding region of the gene (starting at nucleotide 32148).

10468) was identical with that in the 5' end of the gene for the γ chain of rat fibrinogen. The statistical significance of these shorter homologous sequences of DNA are not clear at the present time, particularly since the nucleotide sequences in genes are not random (Table III) and the amount of eukaryotic DNA that factor IX was compared with is extremely small. Nevertheless, these homologous regions appear to be higher than those expected by random chance.

DISCUSSION

Factor IX circulates in blood as a zymogen to a serine protease. This protein contains four or more different potential domains or regions including a Gla domain containing γ -carboxyglutamic acid, two growth factor domains, an acti-

vation peptide or connecting domain, and a catalytic domain. A tentative structure for prepro factor IX showing the location of the seven introns (A-G) and the proposed domains are shown in Figure 7. The prepro leader sequence is divided by intron A at Val -17. The next intron (intron B) follows the first 11 γ -carboxyglutamic acid residues and separates the Gla domain from a stretch of eight amino acids located just prior to the first potential growth factor domain. Potential epidermal growth factor domains have been noted earlier in the vitamin K dependent coagulation factors (Dayhoff, 1978; Banyai et al., 1983; Doolittle et al., 1984), which show considerable amino acid sequence homology (Davie et al., 1979). Intron C at Asp-47 follows the short stretch of eight amino acids in factor IX and precedes the first potential growth factor domain, while intron D at Asp-85 is located between the first




FIGURE 7: Amino acid sequence and tentative structure for prepro factor IX showing the location of the seven introns (A-G). The prepro leader sequence (numbered -46 to -1) is removed during biosynthesis by signal peptidase and a processing protease that hydrolyzes the R-Y bond between -1 and 1. The Glu domain and potential growth factor domains are located within residues 1-145, which constitute the light chain of factor IXa. The activation peptide of 35 residues is released from factor IX by factor XIa during its conversion to factor IXa. The amino acids where this cleavage occurs (R-A and R-V) are circled. The serine protease or catalytic domain of factor IX contains 235 residues including the three principal amino acids participating in catalysis. These three amino acids (H-41, D-89, and S-185) are also circled. Two potential carbohydrate binding sites in the activation peptide are shown by solid diamonds. The proposed disulfide bonds in factor IX have been placed by analogy to those in bovine prothrombin and epidermal growth factor. The single-letter code for amino acids is as follows: A, Ala; R, Arg; N, Asn; D, Asp; C, Cys; Q, Gln; E, Glu; G, Gly; H, His; I, Ile; L, Leu; K, Lys; M, Met; F, Phe; P, Pro; S, Ser; T, Thr; W, Trp; Y, Tyr; V, Val; γ , γ -carboxyglutamic acid; β , β -hydroxyaspartic acid.

and second potential growth factor domains. The fifth intron (intron E) immediately follows the second potential growth factor domain at Val-128. The last two introns in the gene for factor IX (introns F and G) are present in the catalytic domain of the protein. Intron F is the largest intron in the gene (9473 nucleotides) and is located 15 residues after the Val-Val-Gly-Gly sequence, which is generated during the formation of factor IXa by factor XIa (DiScipio et al., 1978). The seventh intron (intron G) is located 12 amino acid residues after the active site His (residue 41 in the heavy chain). The remainder of the catalytic domain (carboxyl-terminal 182 amino acids) is devoid of introns and contains the other two principal residues (Asp-89 and Ser-185) involved in the catalytic activity of the serine protease.

Similar conclusions for the structure of the gene for factor IX have been reported by Anson et al. (1984), who sequenced 5280 nucleotides throughout the gene. The present data are in excellent agreement with their experiments except for the following minor differences: nucleotides -158 and -157 were GA in the present experiments instead of AG, nucleotides 14 and 15 were TC instead of CT, nucleotide 24 was A instead of G, no T was found following nucleotide 6199, nucleotide 32308 was C instead of G, no GACTCT was found following

nucleotide 32841, no T was found following nucleotide 32893, an additional T was found following nucleotide 32915, and, lastly, an additional T was found following nucleotide 32980.

The gene for factor IX contains six major open-reading frames. The first is present in the *KpnI* repeat at the 5' end of the gene (nucleotides -2820 to -1827). It is highly homologous to the amino acid sequence of an open-reading frame previously reported for *KpnI* repetitive sequences (Potter, 1984; Martin et al., 1984). The second large open-reading frame is present in intron A (nucleotides 5292-5706), while the third and fourth are located in intron E (nucleotides 18513-18837 and 18841-19172). Two additional open-reading frames were also found in the complementary strand extending from nucleotides 33355-32795 and 5672-5154. The amino acid sequences predicted by the nucleotides in these open-reading frames showed no significant homology to the amino acid sequences found in the NIH Protein Sequence Database (updated Aug 13, 1984) as analyzed with the computer programs of Intelligenetics. Accordingly, there is no evidence thus far for the presence of any overlapping genes or internal genes within the region coding for factor IX on the X chromosome.

It is of interest to compare the structure of the gene for factor IX with the genes for the other vitamin K dependent

proteins present in plasma, since this family shows considerable amino acid sequence homology (Davie et al., 1979). In our previous studies (Davie et al., 1983), we reported the presence of the first six intervening sequences in the gene for human factor IX, and the fact that the location of the first three were in the same position in the amino acid sequence as the first three introns in the gene for human prothrombin. These first three introns in factor IX, however, show no similarity in size and DNA sequence to the corresponding first three introns in prothrombin, as determined by a computer homology search. The gene for human prothrombin contains 10 additional intervening sequences (Degen et al., 1983; Davie et al., 1983; S. J. Degen and E. W. Davie, unpublished data), and their location in the amino acid sequence of the protein shows little correlation with the last four introns in factor IX. In prothrombin, the Gla domain, however, is followed by two kringle structures (Magnusson et al., 1975) that are unrelated in sequence to the region containing the potential growth factor domains in factor IX.

Protein C, another vitamin K dependent protein present in plasma in a zymogen form, has a genomic structure extremely similar to the gene for factor IX (Foster & Davie, 1984; D. Foster, unpublished results). The gene for protein C, like the gene for factor IX, contains seven intervening sequences, in the coding and 3' noncoding regions, and these seven introns are all located in essentially the same position as the seven introns in factor IX. These include the following positions in the amino acid sequence of prepro protein C: -19, 37/38, 46, 92, and 137 in the light chain and 15/16 and 55 in the heavy chain of activated protein C. These data provide further evidence to support the concept that the vitamin K dependent family of serine proteases present in plasma has evolved from a common ancestral gene. One possible mechanism for these events is that the genetic information coding for the prepro leader, the Gla domain and the potential growth factor domains in factor IX and protein C, is the result of a translocation event(s) during evolution. This could lead to the transfer of these three regions or domains either stepwise or together from a donor chromosome to a second chromosome containing a serine protease or catalytic structure similar to trypsin. It also appears possible that the intervening sequences could play some role in this shuffling of regions or domains since they often appear between domains and in the same relative position in the amino acid sequence of some of the closely related proteins. In an analogous manner, the prepro leader and the Gla domains in prothrombin could result from a translocation event leading to the transfer of these two regions to a serine protease, such as urokinase, plasminogen, tissue plasminogen activator, or factor XII (McMullen & Fujikawa, 1985). These latter four proteins, like prothrombin, all contain one (or more) kringle structure immediately preceding the serine protease portion of the molecules. This type of evolutionary process would be analogous to the tinkering mechanism described by Jacob (1982), which proposes the joining of preexisting DNA fragments to generate new genes that are useful to the organism. This proposed mechanism also suggests that many similar or homologous fragments of DNA sequences will be found in unrelated genes. This is consistent with the present data in which a large number of short sequences of DNA in the gene for factor IX were found to be homologous to sequences present in other unrelated genes. Accordingly, it is possible that the gene for factor IX resulted from the joining of a large number of different fragments of DNA during evolution and this led to the formation of a gene coding for a multifunctional protein. These various functions include a protein that is (1) secreted (prepro leader sequence), (2) binds

calcium (Gla domain), (3) contains a potential growth factor domain (function not known), (4) contains a connecting region that allows the serine protease to circulate in blood in a zymogen form, and (5) contains a serine protease region capable of the hydrolysis of peptide bonds. Secondary mutations could then lead to very specialized properties of factor IX, such as its high substrate specificity.

ACKNOWLEDGMENTS

We thank Dr. Oscar Ratnoff for his generous support of B.G.S., Dr. Sandra Degen for kindly making available the unpublished DNA sequences for the gene for human prothrombin, and Dr. Mike Parker for his assistance in the computer homology searches. We also thank Drs. Dominic Chung, Steven Leytus, and Torben Petersen for helpful discussions and John Ward for excellent technical assistance. We are grateful to Dr. Stanley Gartler for kindly providing the cellular DNA from human 5X fibroblast cells, Dr. Tom Maniatis for making available the human genomic library constructed in λ Charon 4A phage, and Dr. Jon Herriott for his assistance with the computer analyses.

Registry No. DNA (human fibroblast blood coagulation factor IX gene), 96481-17-3; RNA (human fibroblast blood coagulation factor IX specifying messenger), 96481-18-4; pre-blood coagulation factor IX (human fibroblast protein moiety reduced), 96481-19-5; blood coagulation factor IX (human fibroblast protein moiety reduced), 96481-20-8; blood coagulation factor IX (human fibroblast protein moiety), 96481-21-9; blood coagulation factor IXa (human fibroblast protein moiety), 96481-22-0; blood coagulation factor IXa (human fibroblast light chain protein moiety reduced), 96481-23-1; blood coagulation factor IXa (human fibroblast heavy chain protein moiety reduced), 84615-53-2; blood coagulation factor IX, 9001-28-9; blood coagulation factor IXa, 37316-87-3; pre-blood coagulation factor IX, 86352-52-5.

REFERENCES

- Anson, D. S., Choo, K. H., Rees, D. J. G., Giannelli, F., Gould, J. A., Huddleston, J. A., & Brownlee, G. G. (1984) *EMBO J.* 3, 1053-1060.
- Banyai, L., Varadi, A., & Patthy, L. (1983) *FEBS Lett.* 163, 37-41.
- Benoist, C., O'Hare, K., Breathnach, R., & Chambon, P. (1980) *Nucleic Acids Res.* 8, 127-142.
- Benton, W. D., & Davis, R. W. (1977) *Science (Washington, D.C.)* 196, 181-182.
- Berget, S. M. (1984) *Nature (London)* 309, 179-182.
- Biggin, M. D., Gibson, T. T., & Hong, G. F. (1983) *Proc. Natl. Acad. Sci. U.S.A.* 80, 3963-3965.
- Boyd, Y., Buckle, V. J., Munro, E. A., Choo, K. H., Migeon, B. R., & Craig, I. W. (1984) *Ann. Hum. Genet.* 48, 145-152.
- Breathnach, R., & Chambon, P. (1981) *Annu. Rev. Biochem.* 50, 349-383.
- Camerino, G., Grzeschik, K. H., Jaye, M., De La Salle, H., Tolsoshev, P., Lecocq, J. P., Heilig, R., & Mandel, J. L. (1984) *Proc. Natl. Acad. Sci. U.S.A.* 81, 498-502.
- Chance, P. F., Dyer, K. A., Kurachi, K., Yoshitake, S., Ropers, H. H., Wieacker, P., & Gartler, S. M. (1983) *Hum. Genet.* 65, 207-208.
- Choo, K. H., Gould, K. G., Rees, D. J. G., & Brownlee, G. G. (1982) *Nature (London)* 299, 178-180.
- Chung, D. W., Que, B. G., Rixon, M. W., Mace, M., Jr., & Davie, E. W. (1983) *Biochemistry* 22, 3244-3250.
- Davie, E. W., Fujikawa, K., Kurachi, K., & Kisiel, W. (1979) *Adv. Enzymol. Relat. Areas Mol. Biol.* 48, 277-318.
- Davie, E. W., Degen, S. J., Friezner, Yoshitake, S., & Kurachi, K. (1983) *Dev. Biochem.* 25, 45-52.
- Dayhoff, M. O. (1978) *Atlas of Protein Sequences and*

- Structure*, Vol. 5, Suppl. 3, National Biomedical Research Foundation, Washington, D.C.
- Degen, S. J., Friezner, MacGillivray, R. T. A., & Davie, E. W. (1983) *Biochemistry* 22, 2087-2097.
- Deininger, P. L., Jolly, D. J., Rubin, C. M., Friedmann, T., & Schmid, C. W. (1981) *J. Mol. Biol.* 151, 17-33.
- DiGiovanni, L., Haynes, S. R., Misra, R., & Jelinek, W. R. (1983) *Proc. Natl. Acad. Sci. U.S.A.* 80, 6533-6537.
- DiScipio, R. G., Kurachi, K., & Davie, E. W. (1978) *J. Clin. Invest.* 61, 1528-1538.
- Doolittle, R. F., Feng, D. F., & Johnson, M. S. (1984) *Nature (London)* 307, 558-560.
- Efstratiadis, A., Rosakony, J. W., Maniatis, T., Lawn, R. M., O'Connell, C., Spritz, R. A., De Reil, J. K., Forget, B. G., Weissman, S. M., Slightom, J. L., Blechl, A. E., Smithies, O., Baralle, F. E., Shoulders, C. C., & Proudfoot, N. J. (1980) *Cell (Cambridge, Mass.)* 21, 653-668.
- Foster, D., & Davie, E. W. (1984) *Proc. Natl. Acad. Sci. U.S.A.* 81, 4766-4770.
- Frischauf, A. M., Lehrach, H., Poustka, A., & Murray, N. (1983) *J. Mol. Biol.* 170, 827-842.
- Giannelli, F., Choo, K. H., Winship, P. R., Anson, D. S., Rees, D. J. G., Ferrari, N., Rizza, C. R., & Brownlee, G. G. (1984) *Lancet*, 239-241.
- Gitschier, J., Wood, W. I., Goralka, T. M., Wion, K. L., Chen, E. Y., Eaton, D. H., Vehar, G. A., Capon, D. J., & Lawn, R. M. (1984) *Nature (London)* 312, 326-330.
- Goldberg, M. L. (1979) Ph.D. Thesis, Stanford University.
- Guo, L.-H., & Wu, R. (1983) *Methods Enzymol.* 100, 60-96.
- Hedner, U., & Davie, E. W. (1982) in *Hemostasis and Thrombosis* (Colman, R. W., Hirsh, J., Marder, V. J., & Salzman, E. W., Eds.) pp 29-38, Lippincott, Philadelphia.
- Henikoff, S. (1984) *Gene* 28, 351-359.
- Jacob, F. (1982) *The Possible and the Actual*, Pantheon Books, New York.
- Jagadeeswaran, P., Lavelle, D. E., Kaul, R., Mohandas, T., & Warren, S. T. (1984) *Somatic Cell Mol. Genet.* 10, 465-73.
- Jaye, M., De La Salle, H., Schamber, F., Balland, A., Kohli, V., Findeli, A., Tolsloshev, P., & Lecocq, J. P. (1983) *Nucleic Acids Res.* 11, 2325-2335.
- Keller, E. B., & Noon, W. A. (1984) *Proc. Natl. Acad. Sci. U.S.A.* 81, 7417-7420.
- Kozak, M. (1984) *Nucleic Acids Res.* 12, 857-872.
- Kurachi, K., & Davie, E. W. (1982) *Proc. Natl. Acad. Sci. U.S.A.* 79, 6461-6464.
- Lerman, M. I., Thayer, R. E., & Singer, M. F. (1983) *Proc. Natl. Acad. Sci. U.S.A.* 80, 3966-3970.
- Magnusson, S., Petersen, T. E., Sottrup-Jensen, L., & Claey's, H. (1975) in *Proteases and Biological Control* (Reich, E., Rifkin, D. B., & Shaw, E., Eds.) p 123, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY.
- Maniatis, T., Fritsch, E. F., & Sambrook, J. (1982) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY.
- Maniatis, T., Hardison, R. C., Lacy, E., Lauer, J., O'Connell, C., Quon, D., Sim, G. K., & Efstratiadis, A. (1978) *Cell (Cambridge, Mass.)* 15, 687-702.
- Manuelidis, L. (1982) *Nucleic Acids Res.* 10, 3211-3219.
- Martin, S. L., Voliva, C. F., Burton, F. H., Edgell, M. H., & Hutchison, C. A., III (1984) *Proc. Natl. Acad. Sci. U.S.A.* 81, 2308-2312.
- Maxam, A. M., & Gilbert, W. (1980) *Methods Enzymol.* 65, 499-560.
- McGraw, R. A., Davis, L. M., Noyes, C. M., Graham, J. B., Roberts, H. R., & Stafford, D. W. (1984) *Am. Soc. Hematol. Abstr.* 64 (Suppl. 1), 262a.
- McMullen, B. A., & Fujikawa, K. (1985) *J. Biol. Chem.* 260, 5328-5341.
- Melton, D. W., Konecki, D. S., Brennard, J., & Caskey, C. T. (1984) *Proc. Natl. Acad. Sci. U.S.A.* 81, 2147-2151.
- Messing, J., Crea, R., & Seeburg, P. H. (1981) *Nucleic Acids Res.* 9, 309-321.
- Mount, S. M. (1982) *Nucleic Acids Res.* 10, 459-472.
- Nordheim, A., Tesser, P., Azorin, F., Kwon, Y. H., Moller, A., & Rich, A. (1982) *Proc. Natl. Acad. Sci. U.S.A.* 79, 7729-7733.
- Norlander, J., Kempe, T., & Messing, J. (1983) *Gene* 26, 101-106.
- Nussinov, R. (1981) *J. Mol. Biol.* 149, 125-131.
- Peake, I. R., Furlong, B. L., & Bloom, A. L. (1984) *Lancet*, 242-243.
- Poncz, M., Solowiejczyk, D., Ballantine, M., Schwartz, E., & Surrey, S. (1982) *Proc. Natl. Acad. Sci. U.S.A.* 79, 4298-4302.
- Potter, S. S. (1984) *Proc. Natl. Acad. Sci. U.S.A.* 81, 1012-1016.
- Pustell, J., & Kafatos, F. C. (1982a) *Nucleic Acids Res.* 10, 51-59.
- Pustell, J., & Kafatos, F. C. (1982b) *Nucleic Acids Res.* 10, 4765-4782.
- Pustell, J., & Kafatos, F. C. (1984) *Nucleic Acids Res.* 12, 643-655.
- Rich, A., Nordheim, A., & Wang, A. H.-J. (1984) *Annu. Rev. Biochem.* 53, 791-846.
- Rigby, P. W. J., Dieckman, M., Rhodes, C., & Berg, P. (1977) *J. Mol. Biol.* 113, 237-251.
- Sanger, F., Nicklen, S., & Coulson, A. R. (1977) *Proc. Natl. Acad. Sci. U.S.A.* 74, 5463-5467.
- Schmid, C. W., & Jelinek, W. R. (1982) *Science (Washington, D.C.)* 216, 1065-1070.
- Sharp, P. A. (1981) *Cell (Cambridge, Mass.)* 23, 643-646.
- Silhavy, T. J., Berman, M. L., & Enquist, L. W. (1984) *Experiments with Gene Fusion*, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY.
- Singer, M. (1982) *Int. Rev. Cytol.* 76, 67-112.
- Southern, E. M. (1975) *J. Mol. Biol.* 98, 503-517.
- Staden, R. (1977) *Nucleic Acids Res.* 4, 4037-4051.
- Staden, R. (1978) *Nucleic Acids Res.* 5, 1013-1015.
- Toniolo, D., D'Urso, M., Martini, G., Persico, M., Tufano, V., Battistuzzi, G., & Lazzatto, L. (1984) *EMBO J.* 3, 1987-1995.
- Winship, P. R., Anson, D. S., Rizza, C. R., & Brownlee, G. G. (1984) *Nucleic Acids Res.* 12, 8861-8872.
- Wolf, S. F., Dintzis, S., Toniolo, D., Persico, G., Lunnen, K., Axelmann, J., & Migeon, R. (1984a) *Nucleic Acids Res.* 12, 9333-9348.
- Wolf, S. F., Jolly, D. J., Lunnen, K. D., Friedmann, T., & Migeon, B. R. (1984b) *Proc. Natl. Acad. Sci. U.S.A.* 81, 2806-2810.
- Woo, S. L. C. (1979) *Methods Enzymol.* 68, 381-395.
- Yen, P. H., Patel, P., Chinault, A. C., Mohandas, T., & Shapiro, L. J. (1984) *Proc. Natl. Acad. Sci. U.S.A.* 81, 1759-1763.